title: lncap_LNCAPPS4B_B12_Nigericin_0.035_24

value: Nigericin


title: lncap_LNCAPPS4B_H11_UNTREATED_0_24

status: Public on Oct 31 2022

type: SRA

city: New York City

first: Alessandro

last: Vasciaveo

state: NY

address: 1130 Saint Nicholas Ave., 910

department: Department of Systems Biology

country: USA

institute: Columbia University

library_source: transcriptomic

data_processing:
Sequencing was performed in a Hi Seq 2500 sequencer (Illumina) and base calling was performed with Illumina HCS software.
RNASeq reads were mapped for each well to the human reference genome assembly 38 using the STAR aligner (Dobin et al., 2013), version 2.5.2b
Individual counts files were combined across genes and ERCC2 spike-in counts removed, yielding the raw counts file for each cell-line experiment.
Assembly: hg38
Supplementary files format and content: 2 semicolon delinated text files (for 2 cell-lines) with raw gene counts for every gene and every sample

molecule: total RNA

organism: Homo sapiens

source_name: prostate cancer

extract_protocol:
Cells are lysed for PLATE-Seq in Buffer TCL (Qiagen) supplemented with 2-mercaptoethanol in 96-well plates. We transfer 30 μl of cell lysate from each well to a 96-well plate with oligo(dT) grafted to the wells (mRNA TurboCapture Plate, Qiagen) and added 1 μl of 1:100 dilution of ERCC Ex-Fold Spike-Ins (ThermoFisher) to a subset of the sample wells. The plate is then centrifuged at 295 × g for 1 min to eliminate air bubbles followed by incubation for 90 min at room temperature with shaking at 200 rpm. Lysate is then removed from the oligo(dT) capture plate and wells are washed three times with Buffer TCW (Qiagen) using the 96 CO-RE Head of a Hamilton Microlab STAR automated liquid handling system. After drying the plate, mRNA is then eluted by adding 30 μl of elution buffer (nuclease-free water supplemented with 0.4 U μl−1 SUPERaseIN (ThermoFisher)), incubation at 65 °C for 5 min, and incubation at room temperature for 5 min. mRNA samples are then transferred to a new PCR plate (Hard-Shell PCR plate, 96-well, Bio-Rad) using sterile-filter 96-well, 50 μl tips on the Hamilton STAR. To anneal primers for reverse transcription, 3 μl of 100 μM adapter-linked oligo(dT) primers are added to each well along with 10 μl of 5× ProtoScript RT Buffer (New England BioLabs) with the Hamilton STAR CO-RE Head and 1000 μl channel pipetting system (see Supplementary Table 2 for “PLATEseq_oligodTBC” sequences). The plate is then heated to 94 °C for 2 min and placed immediately on ice for 5 min. The remaining components of the reverse transcription master mix including 0.5 mM of each dNTP, 10 mM DTT, 35.8 U of Protoscript II Reverse Transcriptase (New England BioLabs), and water are then added to bring the final reaction volume to 50 μl per well. The plate is then centrifuged at 295 × g for 1 min and incubated at 42 °C for 2 h. At this point, the samples can optionally be frozen at −80 °C. To remove excess primer, 1 μl of a fourfold dilution of Exonuclease I (New England BioLabs) is added to each sample. The Exonculease I reaction is incubated at 25 °C for 1 h. To hydrolyze the RNA, we add 20 μl of a 1:1 mixture of 1 M sodium hydroxide and 0.5 M EDTA to each well and incubate at 65 °C for 15 min. The wells are then pooled together into a single tube to which 80 μl of 12 M hydrochloric acid are added to neutralize the sample. At this point, the pooled sample can optionally be frozen at −80 °C. The pooled, neutralized sample is purified and concentrated using a Qiagen MinElute column using a vacuum apparatus according to the manufacturer’s instructions, and pooled cDNA is eluted in 15 μl of nuclease-free water. For second-strand synthesis, 1 μl of 10 mM dNTP mixture and 1 μl of 100 mM adapter-linked random hexamer primers are added to the pooled cDNA sample. The mixture is then heated to 70 °C for 2 min and immediately placed on ice for 5 min. Next, 2 μl of NEB Buffer 2 (New England BioLabs) and 1 μl of Klenow large fragment DNA polymerase (New England BioLabs) are added and the reaction is incubated at room temperature for 30 min. The reaction is then stopped by addition of EDTA to a final concentration of 50 μM the double-stranded cDNA is purified with two rounds of bead clean-up using AMPure XP beads (Beckman Counter) at a 1:1 bead-to-sample ratio. Finally, the double-stranded cDNA pool is amplified by PCR using Phusion DNA Polymerase (New England BioLabs)
RNA libraries were prepared for sequencing using standard Illumina protocols

treatment_protocol: Cell-lines were treated at a 48-hour IC20 for each drug and RNA was collected at 24 hours to minimize cell-death.

tag: treatment

value: UNTREATED

tag: cell line

value: LNCaP

tag: provider

value: ATCC

tag: vendor id

tag: age

tag: Sex

value: male


title: lncap_LNCAPPS4B_C12_PIK-75_0.03_24


title: lncap_LNCAPPS4B_C11_NH125_0.1_24


title: lncap_LNCAPPS4B_G11_UNTREATED_0_24


title: lncap_LNCAPPS4B_F11_DMSO_0_24

value: DMSO


title: lncap_LNCAPPS4B_A12_Akt Inhibitor IV_0.04_24

value: Akt Inhibitor IV


title: lncap_LNCAPPS4B_A11_BIX01294_0.5_24


title: lncap_LNCAPPS4B_E11_DMSO_0_24


title: lncap_LNCAPPS4B_H10_MNS_1_24

value: MNS


title: lncap_LNCAPPS4B_D11_Cdk/Crk Inhibitor_0.05_24

value: Cdk/Crk Inhibitor


title: lncap_LNCAPPS5A_A4_IKK 16_2_24

value: IKK 16


title: lncap_LNCAPPS4B_B11_PI 3-Kalpha Inhibitor IV_0.23_24

value: PI 3-Kalpha Inhibitor IV


title: lncap_LNCAPPS4B_E10_Cabergoline_0.0001_24

value: Cabergoline


title: lncap_LNCAPPS4B_G10_SRT1720_1_24


title: lncap_LNCAPPS5A_A5_Mibefradil dihydrochloride_2.5_24

value: Mibefradil dihydrochloride


title: lncap_LNCAPPS4B_F12_CCT128930_0.00145_24


title: lncap_LNCAPPS4B_D10_Galeterone_0.0002_24

value: Galeterone


title: lncap_LNCAPPS4B_D12_GSK690693_0.01_24


title: lncap_LNCAPPS4B_G9_Canertinib_0.005_24

value: Canertinib


title: lncap_LNCAPPS4B_C9_Abexinostat_0.01_24

value: Abexinostat


title: lncap_LNCAPPS4B_E9_Binimetinib_0.005_24

value: Binimetinib


title: lncap_LNCAPPS4B_B10_Halofuginone_0.0013_24

value: Halofuginone


title: lncap_LNCAPPS4B_F10_SGI-1776 free base_2.5_24

value: SGI-1776 free base


title: lncap_LNCAPPS4B_D9_Oprozomib_0.005_24

value: Oprozomib

value: LNCaP


title: lncap_LNCAPPS4B_A10_Propranolol_0.002_24

value: Propranolol

value: ATCC

value: male


title: lncap_LNCAPPS4B_F9_Iniparib_0.005_24

value: Iniparib


title: lncap_LNCAPPS4B_H8_Selinexor_0.015_24

value: Selinexor


title: lncap_LNCAPPS4B_E8_Resminostat_0.02_24

value: Resminostat


title: lncap_LNCAPPS4B_F8_Pirarubicin_0.015_24

value: Pirarubicin


title: lncap_LNCAPPS4B_B8_Pevonedistat_0.02_24

value: Pevonedistat


title: lncap_LNCAPPS4B_A9_Plinabulin_0.015_24

value: Plinabulin


title: lncap_LNCAPPS4B_H9_Vindesine_0.005_24

value: Vindesine


title: lncap_LNCAPPS4B_C8_AMG208_0.02_24


title: lncap_LNCAPPS4B_D8_EPZ-6438_0.02_24


title: lncap_LNCAPPS4B_B9_Gedatolisib_0.01_24

value: Gedatolisib


title: lncap_LNCAPPS4B_G7_OTX015_0.03_24


title: lncap_LNCAPPS4B_F7_AVN944_0.04_24


title: lncap_LNCAPPS4B_H6_PX12_0.255_24


title: lncap_LNCAPPS4B_E7_Talazoparib_0.06_24

value: Talazoparib


title: lncap_LNCAPPS4B_C7_ENMD2076_0.2_24


title: lncap_LNCAPPS4B_A7_LY2835219_0.205_24


title: lncap_LNCAPPS4B_G6_Raltitrexed_0.4_24

value: Raltitrexed


title: lncap_LNCAPPS4B_B7_UCN01_0.2_24


title: lncap_LNCAPPS4B_C10_EpothiloneB_0.0002_24

value: EpothiloneB


title: lncap_LNCAPPS4B_G8_Lexibulin_0.015_24

value: Lexibulin


title: lncap_LNCAPPS4B_H7_BIIB021_0.03_24


title: lncap_LNCAPPS4B_D7_P27600_0.075_24


title: lncap_LNCAPPS4B_A8_Prinomastat_0.02_24

value: Prinomastat


title: lncap_LNCAPPS4B_E6_UNTREATED_0_24

value: UNTREATED

value: LNCaP


title: lncap_LNCAPPS4B_H5_Pilaralisib_0.5_24

value: Pilaralisib

value: ATCC


title: lncap_LNCAPPS4B_F6_UNTREATED_0_24

value: male


title: lncap_LNCAPPS4B_H4_Danusertib_1_24

value: Danusertib


title: lncap_LNCAPPS4B_G5_Tasquinimod_0.52_24

value: Tasquinimod


title: lncap_LNCAPPS4B_B5_Tandutinib_1_24

value: Tandutinib


title: lncap_LNCAPPS4B_C5_Tirapazamine_1_24

value: Tirapazamine


title: lncap_LNCAPPS4B_A5_Talampanel_1_24

value: Talampanel


title: lncap_LNCAPPS4B_G4_Atrasentan_1.5_24

value: Atrasentan


title: lncap_LNCAPPS4B_D5_AP1903_1_24


title: lncap_LNCAPPS4B_B6_Baricitinib_0.415_24

value: Baricitinib


title: lncap_LNCAPPS4B_F4_Satraplatin_1.5_24

value: Satraplatin


title: lncap_LNCAPPS4B_D4_Tariquidar_1.5_24

value: Tariquidar


title: lncap_LNCAPPS4B_B4_Tasisulam_2_24

value: Tasisulam


title: lncap_LNCAPPS4B_C4_Triapine_2_24

value: Triapine


title: lncap_LNCAPPS4B_H3_ONO4059_2_24


title: lncap_LNCAPPS4B_G3_Idasanutlin_2_24

value: Idasanutlin


title: lncap_LNCAPPS4B_A4_NLG919_2_24


title: lncap_LNCAPPS4B_F3_Gilteritinib_2_24

value: Gilteritinib


title: lncap_LNCAPPS4B_E3_Refametinib_2_24

value: Refametinib

value: LNCaP


title: lncap_LNCAPPS4B_C6_DMSO_0_24

value: DMSO

value: ATCC


title: lncap_LNCAPPS4B_D6_DMSO_0_24

value: male


title: lncap_LNCAPPS4B_E5_Picoplatin_1_24

value: Picoplatin


title: lncap_LNCAPPS4B_C3_Ezatiostat_2.5_24

value: Ezatiostat


title: lncap_LNCAPPS4B_D3_Birinapant_2_24

value: Birinapant


title: lncap_LNCAPPS4B_F5_Entospletinib_0.5_24

value: Entospletinib


title: lncap_LNCAPPS4B_B3_Vadimezan_2.5_24

value: Vadimezan


title: lncap_LNCAPPS4B_A6_Pacritinib_0.49_24

value: Pacritinib


title: lncap_LNCAPPS4B_G2_SCIO469_4.5_24


title: lncap_LNCAPPS4B_A3_LY2228820_3.5_24


title: lncap_LNCAPPS4B_F2_EPZ5676_6_24


title: lncap_LNCAPPS4B_E4_Voreloxin_1.5_24

value: Voreloxin


title: lncap_LNCAPPS4B_C2_UNTREATED_0_24

value: UNTREATED


title: lncap_LNCAPPS4B_A2_DMSO_0_24


title: lncap_LNCAPPS4B_F1_ODM201_9.5_24


title: lncap_LNCAPPS4B_D1_ATN161_10_24


title: lncap_LNCAPPS4B_B2_DMSO_0_24


title: lncap_LNCAPPS4A_H12_PI-103_0.0002_24


title: lncap_LNCAPPS4B_A1_Savolitinib_10_24

value: Savolitinib


title: lncap_LNCAPPS4B_B1_Perifosine_10_24

value: Perifosine


title: lncap_LNCAPPS4B_H2_LCL161_3.5_24


title: lncap_LNCAPPS4A_H11_UNTREATED_0_24


title: lncap_LNCAPPS4A_E12_LAQ824_0.01_24


title: lncap_LNCAPPS4A_C12_PIK-75_0.03_24


title: lncap_LNCAPPS4A_D12_GSK690693_0.01_24


title: lncap_LNCAPPS4A_A12_Akt Inhibitor IV_0.04_24

value: Akt Inhibitor IV


title: lncap_LNCAPPS4A_B12_Nigericin_0.035_24

value: Nigericin


title: lncap_LNCAPPS4A_F11_DMSO_0_24


title: lncap_LNCAPPS4A_F12_CCT128930_0.00145_24


title: lncap_LNCAPPS4B_D2_UNTREATED_0_24


title: lncap_LNCAPPS4A_E11_DMSO_0_24


title: lncap_LNCAPPS4A_D11_Cdk/Crk Inhibitor_0.05_24

value: Cdk/Crk Inhibitor


title: lncap_LNCAPPS4A_G11_UNTREATED_0_24

value: LNCaP


title: lncap_LNCAPPS4B_G1_Pixantrone_9_24

value: Pixantrone


title: lncap_LNCAPPS4A_C11_NH125_0.1_24

value: ATCC


title: lncap_LNCAPPS4B_E1_AVL292_9.5_24

value: male


title: lncap_LNCAPPS4B_E2_Glasdegib_6.5_24

value: Glasdegib


title: lncap_LNCAPPS4B_H1_Fotemustine_7_24

value: Fotemustine


title: lncap_LNCAPPS4A_B11_PI 3-Kalpha Inhibitor IV_0.23_24

value: PI 3-Kalpha Inhibitor IV


title: lncap_LNCAPPS4B_C1_ADH1_10_24


title: lncap_LNCAPPS4A_G12_PP-121_0.0011_24


title: lncap_LNCAPPS4A_G10_SRT1720_1_24


title: lncap_LNCAPPS4A_A11_BIX01294_0.5_24


title: lncap_LNCAPPS4A_H10_MNS_1_24

value: MNS


title: lncap_LNCAPPS4A_F10_SGI-1776 free base_2.5_24

value: SGI-1776 free base


title: lncap_LNCAPPS4A_E10_Cabergoline_0.0001_24

value: Cabergoline


title: lncap_LNCAPPS4A_B10_Halofuginone_0.0013_24

value: Halofuginone


title: lncap_LNCAPPS4A_D10_Galeterone_0.0002_24

value: Galeterone


title: lncap_LNCAPPS4A_H9_Vindesine_0.005_24

value: Vindesine


title: lncap_LNCAPPS4A_G9_Canertinib_0.005_24

value: Canertinib


title: lncap_LNCAPPS4A_D9_Oprozomib_0.005_24

value: Oprozomib


title: lncap_LNCAPPS4A_A10_Propranolol_0.002_24

value: Propranolol


title: lncap_LNCAPPS4A_E9_Binimetinib_0.005_24

value: Binimetinib


title: lncap_LNCAPPS4A_A9_Plinabulin_0.015_24

value: Plinabulin

value: LNCaP


title: lncap_LNCAPPS4A_H8_Selinexor_0.015_24

value: Selinexor

value: ATCC


title: lncap_LNCAPPS4A_B9_Gedatolisib_0.01_24

value: Gedatolisib

value: male


title: lncap_LNCAPPS4A_C10_EpothiloneB_0.0002_24

value: EpothiloneB


title: lncap_LNCAPPS4A_F9_Iniparib_0.005_24

value: Iniparib


title: lncap_LNCAPPS4A_F8_Pirarubicin_0.015_24

value: Pirarubicin


title: lncap_LNCAPPS4A_C9_Abexinostat_0.01_24

value: Abexinostat


title: lncap_LNCAPPS4A_C8_AMG208_0.02_24


title: lncap_LNCAPPS4A_D8_EPZ-6438_0.02_24


title: lncap_LNCAPPS4A_B8_Pevonedistat_0.02_24

value: Pevonedistat


title: lncap_LNCAPPS4A_A8_Prinomastat_0.02_24

value: Prinomastat


title: lncap_LNCAPPS4A_H7_BIIB021_0.03_24


title: lncap_LNCAPPS4A_C7_ENMD2076_0.2_24


title: lncap_LNCAPPS4A_A7_LY2835219_0.205_24


title: lncap_LNCAPPS4A_E7_Talazoparib_0.06_24

value: Talazoparib


title: lncap_LNCAPPS4A_D7_P27600_0.075_24


title: lncap_LNCAPPS4A_G6_Raltitrexed_0.4_24

value: Raltitrexed


title: lncap_LNCAPPS4A_G8_Lexibulin_0.015_24

value: Lexibulin


title: lncap_LNCAPPS4A_F7_AVN944_0.04_24


title: lncap_LNCAPPS4A_B7_UCN01_0.2_24


title: lncap_LNCAPPS4A_E6_UNTREATED_0_24

value: UNTREATED


title: lncap_LNCAPPS4A_F6_UNTREATED_0_24


title: lncap_LNCAPPS4A_E8_Resminostat_0.02_24

value: Resminostat


title: lncap_LNCAPPS4A_D6_DMSO_0_24

value: DMSO


title: lncap_LNCAPPS4A_C6_DMSO_0_24

value: LNCaP


title: lncap_LNCAPPS4A_H5_Pilaralisib_0.5_24

value: Pilaralisib


title: lncap_LNCAPPS4A_A6_Pacritinib_0.49_24

value: Pacritinib

value: ATCC


title: lncap_LNCAPPS4A_B6_Baricitinib_0.415_24

value: Baricitinib

value: male


title: lncap_LNCAPPS4A_F5_Entospletinib_0.5_24

value: Entospletinib


title: lncap_LNCAPPS4A_D5_AP1903_1_24


title: lncap_LNCAPPS4A_B5_Tandutinib_1_24

value: Tandutinib


title: lncap_LNCAPPS4A_E5_Picoplatin_1_24

value: Picoplatin


title: lncap_LNCAPPS4A_A5_Talampanel_1_24

value: Talampanel


title: lncap_LNCAPPS4A_C5_Tirapazamine_1_24

value: Tirapazamine


title: lncap_LNCAPPS4A_E4_Voreloxin_1.5_24

value: Voreloxin


title: lncap_LNCAPPS4A_G5_Tasquinimod_0.52_24

value: Tasquinimod


title: lncap_LNCAPPS4A_F4_Satraplatin_1.5_24

value: Satraplatin


title: lncap_LNCAPPS4A_D4_Tariquidar_1.5_24

value: Tariquidar


title: lncap_LNCAPPS4A_C4_Triapine_2_24

value: Triapine


title: lncap_LNCAPPS4A_G4_Atrasentan_1.5_24

value: Atrasentan


title: lncap_LNCAPPS4A_A4_NLG919_2_24

value: LNCaP


title: lncap_LNCAPPS4A_H3_ONO4059_2_24


title: lncap_LNCAPPS4A_G3_Idasanutlin_2_24

value: Idasanutlin


title: lncap_LNCAPPS4A_D3_Birinapant_2_24

value: Birinapant


title: lncap_LNCAPPS4A_F3_Gilteritinib_2_24

value: Gilteritinib

value: ATCC


title: lncap_LNCAPPS4A_B3_Vadimezan_2.5_24

value: Vadimezan

value: male


title: lncap_LNCAPPS4A_A3_LY2228820_3.5_24


title: lncap_LNCAPPS4A_H4_Danusertib_1_24

value: Danusertib


title: lncap_LNCAPPS4A_H2_LCL161_3.5_24


title: lncap_LNCAPPS4A_H6_PX12_0.255_24


title: lncap_LNCAPPS4A_G2_SCIO469_4.5_24


title: lncap_LNCAPPS4A_E2_Glasdegib_6.5_24

value: Glasdegib


title: lncap_LNCAPPS4A_C2_UNTREATED_0_24

value: UNTREATED


title: lncap_LNCAPPS4A_D2_UNTREATED_0_24


title: lncap_LNCAPPS4A_F2_EPZ5676_6_24


title: lncap_LNCAPPS4A_F1_ODM201_9.5_24


title: lncap_LNCAPPS4A_H1_Fotemustine_7_24

value: Fotemustine


title: lncap_LNCAPPS4A_A2_DMSO_0_24

value: DMSO


title: lncap_LNCAPPS4A_B2_DMSO_0_24


title: lncap_LNCAPPS4A_B4_Tasisulam_2_24

value: Tasisulam


title: lncap_LNCAPPS4A_B1_Perifosine_10_24

value: Perifosine


title: lncap_LNCAPPS4A_E1_AVL292_9.5_24


title: lncap_LNCAPPS4A_C1_ADH1_10_24


title: lncap_LNCAPPS4A_D1_ATN161_10_24


title: lncap_LNCAPPS3B_F12_Cilengitide_0.0003_24

value: Cilengitide


title: lncap_LNCAPPS4A_G1_Pixantrone_9_24

value: Pixantrone


title: lncap_LNCAPPS3B_G12_Cyproterone_0.165_24

value: Cyproterone


title: lncap_LNCAPPS3B_H12_Vatalanib_0.115_24

value: Vatalanib

value: LNCaP


title: lncap_LNCAPPS3B_E12_Sotrastaurin_3_24

value: Sotrastaurin


title: lncap_LNCAPPS4A_C3_Ezatiostat_2.5_24

value: Ezatiostat


title: lncap_LNCAPPS4A_E3_Refametinib_2_24

value: Refametinib

value: ATCC


title: lncap_LNCAPPS3B_B12_Calcitriol_0.0001_24

value: Calcitriol

value: male


title: lncap_LNCAPPS3B_A12_Duvelisib_0.02_24

value: Duvelisib


title: lncap_LNCAPPS3B_F11_DMSO_0_24


title: lncap_LNCAPPS3B_G11_UNTREATED_0_24

value: UNTREATED


title: lncap_LNCAPPS3B_H11_UNTREATED_0_24


title: lncap_LNCAPPS3B_C12_Volasertib_0.015_24

value: Volasertib


title: lncap_LNCAPPS3B_D11_MK0752_0.0003_24


title: lncap_LNCAPPS3B_E11_DMSO_0_24

value: DMSO


title: lncap_LNCAPPS3B_C11_Momelotinib_1.5_24

value: Momelotinib


title: lncap_LNCAPPS3B_B11_LY3023414_0.00095_24


title: lncap_LNCAPPS3B_A11_Pracinostat_0.13_24

value: Pracinostat


title: lncap_LNCAPPS3B_H10_CC223_0.0003_24


title: lncap_LNCAPPS3B_E10_RO4929097_1_24


title: lncap_LNCAPPS3B_F10_MLN2480_6.5_24


title: lncap_LNCAPPS3B_D10_Enasidenib_1_24

value: Enasidenib


title: lncap_LNCAPPS4A_A1_Savolitinib_10_24

value: Savolitinib


title: lncap_LNCAPPS3B_G10_INK128_0.005_24


title: lncap_LNCAPPS3B_B10_AMG337_9.5_24


title: lncap_LNCAPPS3B_C10_Linsitinib_9.5_24

value: Linsitinib


title: lncap_LNCAPPS3B_D9_AZ12456623_0.02_24


title: lncap_LNCAPPS3B_B9_Azacitidine_1_24

value: Azacitidine


title: lncap_LNCAPPS3B_H9_AZ13064550_0.0003_24

value: LNCaP


title: lncap_LNCAPPS3B_A9_GDC0068_0.005_24


title: lncap_LNCAPPS3B_F9_Tacedinaline_1_24

value: Tacedinaline


title: lncap_LNCAPPS3B_C9_Rucaparib_3_24

value: Rucaparib


title: lncap_LNCAPPS3B_G9_AZ12609721_0.02_24


title: lncap_LNCAPPS3B_A10_Mocetinostat_0.185_24

value: Mocetinostat


title: lncap_LNCAPPS3B_E9_CPI613_10_24

value: ATCC


title: lncap_LNCAPPS3B_H8_Triciribine_1_24

value: Triciribine


title: lncap_LNCAPPS3B_D8_Galunisertib_2.5_24

value: Galunisertib

value: male


title: lncap_LNCAPPS3B_F8_AZ12823138_0.02_24


title: lncap_LNCAPPS3B_E8_Quizartinib_0.5_24

value: Quizartinib


title: lncap_LNCAPPS3B_C8_MGCD265_1_24


title: lncap_LNCAPPS3B_G8_AZ12419304_0.001_24


title: lncap_LNCAPPS3B_B8_Enzastaurin_0.12_24

value: Enzastaurin


title: lncap_LNCAPPS3B_A8_Dovitinib_0.5_24

value: Dovitinib


title: lncap_LNCAPPS3B_H7_PF04691502_0.035_24


title: lncap_LNCAPPS3B_E7_Ganetespib_0.015_24

value: Ganetespib


title: lncap_LNCAPPS3B_F7_Rocilinostat_0.16_24

value: Rocilinostat


title: lncap_LNCAPPS3B_G7_LY2603618_1_24


title: lncap_LNCAPPS3B_D7_Crenolanib_0.145_24

value: Crenolanib


title: lncap_LNCAPPS3B_B7_Copanlisib_0.16_24

value: Copanlisib


title: lncap_LNCAPPS3B_A7_Pimasertib_1_24

value: Pimasertib


title: lncap_LNCAPPS3B_H6_Tivozanib_0.175_24

value: Tivozanib


title: lncap_LNCAPPS3B_C7_Lonafarnib_1_24

value: Lonafarnib

value: LNCaP


title: lncap_LNCAPPS3B_F6_UNTREATED_0_24

value: UNTREATED


title: lncap_LNCAPPS3B_E6_UNTREATED_0_24


title: lncap_LNCAPPS3B_D6_DMSO_0_24

value: DMSO


title: lncap_LNCAPPS3B_G6_Nintedanib_0.135_24

value: Nintedanib

value: ATCC


title: lncap_LNCAPPS3B_D5_Varlitinib_1_24

value: Varlitinib


title: lncap_LNCAPPS3B_F5_Eniluracil_4_24

value: Eniluracil

value: male


title: lncap_LNCAPPS3B_C6_DMSO_0_24


title: lncap_LNCAPPS3B_A6_Saridegib_1_24

value: Saridegib


title: lncap_LNCAPPS3B_G5_CP724714_10_24


title: lncap_LNCAPPS3B_H5_Apremilast_0.5_24

value: Apremilast


title: lncap_LNCAPPS3B_B6_RAF265_0.005_24


title: lncap_LNCAPPS3B_E5_AT9283_1_24


title: lncap_LNCAPPS3B_C5_Cediranib_0.2_24

value: Cediranib


title: lncap_LNCAPPS3B_B5_TAK700_10_24


title: lncap_LNCAPPS3B_A5_EpothiloneD_0.04_24

value: EpothiloneD


title: lncap_LNCAPPS3B_H4_Zibotentan_1.5_24

value: Zibotentan


title: lncap_LNCAPPS3B_F4_Brigatinib_3.5_24

value: Brigatinib


title: lncap_LNCAPPS3B_E4_Dacomitinib_0.05_24

value: Dacomitinib


title: lncap_LNCAPPS3B_D4_Combretastatin_0.2_24

value: Combretastatin


title: lncap_LNCAPPS3B_G4_Givinostat_0.08_24

value: Givinostat


title: lncap_LNCAPPS3B_C4_Telatinib_1_24

value: Telatinib

value: LNCaP


title: lncap_LNCAPPS3B_B4_Amonafide_1_24

value: Amonafide


title: lncap_LNCAPPS3B_H3_Onalespib_0.01_24

value: Onalespib


title: lncap_LNCAPPS3B_A4_ABT888_10_24

value: ATCC


title: lncap_LNCAPPS3B_G3_ABT751_1_24


title: lncap_LNCAPPS3B_F3_Ispinesib_0.025_24

value: Ispinesib


title: lncap_LNCAPPS3B_C3_AZD5069_7_24


title: lncap_LNCAPPS3B_B3_AMG900_2.5_24


title: lncap_LNCAPPS3B_A3_AEE788_0.17_24


title: lncap_LNCAPPS3B_D3_TAK733_0.265_24


title: lncap_LNCAPPS4A_G7_OTX015_0.03_24


title: lncap_LNCAPPS3B_E3_Acalabrutinib_1.5_24

value: Acalabrutinib


title: lncap_LNCAPPS3B_E2_Valproic acid_2_24

value: Valproic acid

value: male


title: lncap_LNCAPPS3B_F2_ARN509_5_24


title: lncap_LNCAPPS3B_G2_Banoxantrone_5.5_24

value: Banoxantrone


title: lncap_LNCAPPS3B_B2_DMSO_0_24

value: DMSO


title: lncap_LNCAPPS3B_H1_Phenelzine_1_24

value: Phenelzine


title: lncap_LNCAPPS3B_A2_DMSO_0_24


title: lncap_LNCAPPS3B_F1_Aminopterin_1_24

value: Aminopterin


title: lncap_LNCAPPS3B_C2_UNTREATED_0_24

value: UNTREATED


title: lncap_LNCAPPS3B_D1_Cyclosporine_10_24

value: Cyclosporine


title: lncap_LNCAPPS3B_H2_Icotinib_5.5_24

value: Icotinib


title: lncap_LNCAPPS3B_D2_UNTREATED_0_24


title: lncap_LNCAPPS3B_G1_Berberine_7_24

value: Berberine


title: lncap_LNCAPPS3B_B1_Hydroxychloroquine_0.5_24

value: Hydroxychloroquine


title: lncap_LNCAPPS3A_G12_Cyproterone_0.165_24

value: Cyproterone

value: LNCaP


title: lncap_LNCAPPS3B_A1_Mycophenolate_6.5_24

value: Mycophenolate


title: lncap_LNCAPPS3B_E1_Tacrolimus_10_24

value: Tacrolimus

value: ATCC


title: lncap_LNCAPPS3A_F12_Cilengitide_0.0003_24

value: Cilengitide


title: lncap_LNCAPPS3A_H12_Vatalanib_0.115_24

value: Vatalanib


title: lncap_LNCAPPS3A_E12_Sotrastaurin_3_24

value: Sotrastaurin

value: male


title: lncap_LNCAPPS3A_C12_Volasertib_0.015_24

value: Volasertib


title: lncap_LNCAPPS3A_D12_SAR245409_0.00025_24


title: lncap_LNCAPPS3A_A12_Duvelisib_0.02_24

value: Duvelisib


title: lncap_LNCAPPS3A_H11_UNTREATED_0_24


title: lncap_LNCAPPS3A_G11_UNTREATED_0_24


title: lncap_LNCAPPS3A_E11_DMSO_0_24

value: DMSO


title: lncap_LNCAPPS3A_F11_DMSO_0_24


title: lncap_LNCAPPS3A_C11_Momelotinib_1.5_24

value: Momelotinib


title: lncap_LNCAPPS3A_D11_MK0752_0.0003_24


title: lncap_LNCAPPS3A_B11_LY3023414_0.00095_24


title: lncap_LNCAPPS3A_D10_Enasidenib_1_24

value: Enasidenib


title: lncap_LNCAPPS3A_E10_RO4929097_1_24


title: lncap_LNCAPPS3A_F10_MLN2480_6.5_24


title: lncap_LNCAPPS3A_C10_Linsitinib_9.5_24

value: Linsitinib


title: lncap_LNCAPPS3A_B10_AMG337_9.5_24


title: lncap_LNCAPPS3A_A10_Mocetinostat_0.185_24

value: Mocetinostat


title: lncap_LNCAPPS3B_C1_Aspirin_10_24

value: Aspirin


title: lncap_LNCAPPS3A_H9_AZ13064550_0.0003_24


title: lncap_LNCAPPS3A_G9_AZ12609721_0.02_24


title: lncap_LNCAPPS3A_B12_Calcitriol_0.0001_24

value: Calcitriol


title: lncap_LNCAPPS3A_F9_Tacedinaline_1_24

value: Tacedinaline

value: LNCaP


title: lncap_LNCAPPS3A_G10_INK128_0.005_24


title: lncap_LNCAPPS3A_B9_Azacitidine_1_24

value: Azacitidine


title: lncap_LNCAPPS3A_H8_Triciribine_1_24

value: Triciribine

value: ATCC


title: lncap_LNCAPPS3A_C9_Rucaparib_3_24

value: Rucaparib


title: lncap_LNCAPPS3A_D9_AZ12456623_0.02_24


title: lncap_LNCAPPS3A_F8_AZ12823138_0.02_24


title: lncap_LNCAPPS3A_G8_AZ12419304_0.001_24


title: lncap_LNCAPPS3A_D8_Galunisertib_2.5_24

value: Galunisertib


title: lncap_LNCAPPS3A_E8_Quizartinib_0.5_24

value: Quizartinib

value: male


title: lncap_LNCAPPS3A_A11_Pracinostat_0.13_24

value: Pracinostat


title: lncap_LNCAPPS3A_H10_CC223_0.0003_24


title: lncap_LNCAPPS3A_C8_MGCD265_1_24


title: lncap_LNCAPPS3A_B8_Enzastaurin_0.12_24

value: Enzastaurin


title: lncap_LNCAPPS3A_A8_Dovitinib_0.5_24

value: Dovitinib


title: lncap_LNCAPPS3A_E9_CPI613_10_24


title: lncap_LNCAPPS3A_G7_LY2603618_1_24


title: lncap_LNCAPPS3A_H7_PF04691502_0.035_24


title: lncap_LNCAPPS3A_E7_Ganetespib_0.015_24

value: Ganetespib


title: lncap_LNCAPPS3A_D7_Crenolanib_0.145_24

value: Crenolanib


title: lncap_LNCAPPS3A_B7_Copanlisib_0.16_24

value: Copanlisib


title: lncap_LNCAPPS3A_F7_Rocilinostat_0.16_24

value: Rocilinostat


title: lncap_LNCAPPS3A_C7_Lonafarnib_1_24

value: Lonafarnib


title: lncap_LNCAPPS3A_A9_GDC0068_0.005_24


title: lncap_LNCAPPS3A_G6_Nintedanib_0.135_24

value: Nintedanib


title: lncap_LNCAPPS3A_A7_Pimasertib_1_24

value: Pimasertib

value: LNCaP


title: lncap_LNCAPPS3A_H6_Tivozanib_0.175_24

value: Tivozanib


title: lncap_LNCAPPS3A_E6_UNTREATED_0_24

value: UNTREATED

value: ATCC


title: lncap_LNCAPPS3A_C6_DMSO_0_24

value: DMSO


title: lncap_LNCAPPS3A_B6_RAF265_0.005_24


title: lncap_LNCAPPS3A_G5_CP724714_10_24


title: lncap_LNCAPPS3A_A6_Saridegib_1_24

value: Saridegib


title: lncap_LNCAPPS3A_H5_Apremilast_0.5_24

value: Apremilast

value: male


title: lncap_LNCAPPS3A_F5_Eniluracil_4_24

value: Eniluracil


title: lncap_LNCAPPS3A_E5_AT9283_1_24


title: lncap_LNCAPPS3A_D5_Varlitinib_1_24

value: Varlitinib


title: lncap_LNCAPPS3A_B5_TAK700_10_24


title: lncap_LNCAPPS3A_C5_Cediranib_0.2_24

value: Cediranib


title: lncap_LNCAPPS3A_H4_Zibotentan_1.5_24

value: Zibotentan


title: lncap_LNCAPPS3A_A5_EpothiloneD_0.04_24

value: EpothiloneD


title: lncap_LNCAPPS3A_G4_Givinostat_0.08_24

value: Givinostat


title: lncap_LNCAPPS3A_A4_ABT888_10_24


title: lncap_LNCAPPS3A_E4_Dacomitinib_0.05_24

value: Dacomitinib


title: lncap_LNCAPPS3A_H3_Onalespib_0.01_24

value: Onalespib


title: lncap_LNCAPPS3A_F3_Ispinesib_0.025_24

value: Ispinesib


title: lncap_LNCAPPS3A_G3_ABT751_1_24

value: LNCaP


title: lncap_LNCAPPS3A_C4_Telatinib_1_24

value: Telatinib


title: lncap_LNCAPPS3A_B3_AMG900_2.5_24


title: lncap_LNCAPPS3A_E3_Acalabrutinib_1.5_24

value: Acalabrutinib


title: lncap_LNCAPPS3B_D12_SAR245409_0.00025_24

value: ATCC


title: lncap_LNCAPPS3A_D6_DMSO_0_24

value: DMSO


title: lncap_LNCAPPS3A_D3_TAK733_0.265_24


title: lncap_LNCAPPS3A_A3_AEE788_0.17_24


title: lncap_LNCAPPS3A_F6_UNTREATED_0_24

value: UNTREATED


title: lncap_LNCAPPS3A_G2_Banoxantrone_5.5_24

value: Banoxantrone


title: lncap_LNCAPPS3A_C2_UNTREATED_0_24

value: male


title: lncap_LNCAPPS3A_F2_ARN509_5_24


title: lncap_LNCAPPS3A_E2_Valproic acid_2_24

value: Valproic acid


title: lncap_LNCAPPS3A_A2_DMSO_0_24


title: lncap_LNCAPPS3A_H1_Phenelzine_1_24

value: Phenelzine


title: lncap_LNCAPPS3A_F4_Brigatinib_3.5_24

value: Brigatinib


title: lncap_LNCAPPS3A_F1_Aminopterin_1_24

value: Aminopterin


title: lncap_LNCAPPS3A_D4_Combretastatin_0.2_24

value: Combretastatin


title: lncap_LNCAPPS3A_E1_Tacrolimus_10_24

value: Tacrolimus


title: lncap_LNCAPPS3A_B4_Amonafide_1_24

value: Amonafide


title: lncap_LNCAPPS3A_H2_Icotinib_5.5_24

value: Icotinib


title: lncap_LNCAPPS3A_B1_Hydroxychloroquine_0.5_24

value: Hydroxychloroquine


title: lncap_LNCAPPS3A_C3_AZD5069_7_24

value: LNCaP


title: lncap_LNCAPPS3A_C1_Aspirin_10_24

value: Aspirin


title: lncap_LNCAPPS2B_H12_Dactinomycin_0.00175_24

value: Dactinomycin


title: lncap_LNCAPPS2B_G12_Erlotinib_0.01_24

value: Erlotinib

value: ATCC


title: lncap_LNCAPPS3A_A1_Mycophenolate_6.5_24

value: Mycophenolate


title: lncap_LNCAPPS2B_E12_Vorinostat_0.28_24

value: Vorinostat


title: lncap_LNCAPPS2B_D12_Daunorubicin_0.045_24

value: Daunorubicin

value: male


title: lncap_LNCAPPS3A_D2_UNTREATED_0_24

value: UNTREATED


title: lncap_LNCAPPS2B_B12_Tofacitinib_0.305_24

value: Tofacitinib


title: lncap_LNCAPPS3A_B2_DMSO_0_24

value: DMSO


title: lncap_LNCAPPS2B_C12_Thiotepa_0.02_24

value: Thiotepa


title: lncap_LNCAPPS3A_G1_Berberine_7_24

value: Berberine


title: lncap_LNCAPPS2B_A12_Busulfan_0.295_24

value: Busulfan


title: lncap_LNCAPPS2B_G11_UNTREATED_0_24


title: lncap_LNCAPPS2B_F11_DMSO_0_24


title: lncap_LNCAPPS2B_H11_UNTREATED_0_24


title: lncap_LNCAPPS3A_D1_Cyclosporine_10_24

value: Cyclosporine


title: lncap_LNCAPPS2B_F12_Idarubicin_0.02_24

value: Idarubicin


title: lncap_LNCAPPS2B_D10_GDC0941_0.5_24

value: LNCaP


title: lncap_LNCAPPS2B_F10_YM155_0.07_24


title: lncap_LNCAPPS2B_G10_Entinostat_0.5_24

value: Entinostat


title: lncap_LNCAPPS2B_B10_SB743921_0.13_24


title: lncap_LNCAPPS2B_H10_Flavopiridol_0.055_24

value: Flavopiridol


title: lncap_LNCAPPS2B_A11_Rigosertib_0.1_24

value: Rigosertib


title: lncap_LNCAPPS2B_H9_Obatoclax Mesylate_0.335_24

value: Obatoclax Mesylate

value: ATCC


title: lncap_LNCAPPS2B_A10_MK1775_0.24_24


title: lncap_LNCAPPS2B_B11_Axitinib_0.14_24

value: Axitinib


title: lncap_LNCAPPS2B_C11_Disulfiram_0.01_24

value: Disulfiram


title: lncap_LNCAPPS2B_C10_SNX2112_0.285_24

value: male


title: lncap_LNCAPPS2B_E10_KX2391_0.2_24


title: lncap_LNCAPPS2B_D9_Alisertib_10_24

value: Alisertib


title: lncap_LNCAPPS2B_E11_DMSO_0_24


title: lncap_LNCAPPS2B_C9_Foretinib_2.5_24

value: Foretinib


title: lncap_LNCAPPS2B_A9_Amuvatinib_0.02_24

value: Amuvatinib


title: lncap_LNCAPPS2B_G8_Tivantinib_1.5_24

value: Tivantinib


title: lncap_LNCAPPS2B_H8_HMN214_0.5_24


title: lncap_LNCAPPS2B_F8_Linifanib_1_24

value: Linifanib


title: lncap_LNCAPPS2B_D11_Megestrol_0.045_24

value: Megestrol


title: lncap_LNCAPPS2B_B9_MK2206_0.01_24


title: lncap_LNCAPPS2B_C8_KW2449_8_24


title: lncap_LNCAPPS2B_B8_Cinacalcet_2_24

value: Cinacalcet


title: lncap_LNCAPPS2B_D8_JNJ26854165_0.155_24


title: lncap_LNCAPPS2B_A8_BI2536_1_24


title: lncap_LNCAPPS2B_H7_GSK461364_0.5_24


title: lncap_LNCAPPS2B_G9_Epigallocatechin_0.5_24

value: Epigallocatechin


title: lncap_LNCAPPS2B_F9_Neratinib_0.225_24

value: Neratinib

value: LNCaP


title: lncap_LNCAPPS2B_E9_Dinaciclib_0.015_24

value: Dinaciclib


title: lncap_LNCAPPS2B_F7_PD0325901_0.5_24


title: lncap_LNCAPPS2B_A7_AZD5363_0.035_24


title: lncap_LNCAPPS2B_D7_Bafetinib_7_24

value: Bafetinib


title: lncap_LNCAPPS2B_E7_PKC412_10_24


title: lncap_LNCAPPS2B_F6_UNTREATED_0_24

value: UNTREATED


title: lncap_LNCAPPS2B_G7_Brivanib_10_24

value: Brivanib

value: ATCC


title: lncap_LNCAPPS2B_C7_Motesanib_1_24

value: Motesanib


title: lncap_LNCAPPS2B_B7_Alpelisib_0.37_24

value: Alpelisib

value: male


title: lncap_LNCAPPS2B_H6_Navitoclax_0.5_24

value: Navitoclax


title: lncap_LNCAPPS2B_G6_AZD1480_0.13_24


title: lncap_LNCAPPS2B_D6_DMSO_0_24

value: DMSO


title: lncap_LNCAPPS2B_C6_DMSO_0_24


title: lncap_LNCAPPS2B_E8_BGJ398_8_24


title: lncap_LNCAPPS2B_B6_Bardoxolone Methyl_1_24

value: Bardoxolone Methyl


title: lncap_LNCAPPS2B_A6_Elesclomol_0.02_24

value: Elesclomol


title: lncap_LNCAPPS2B_H5_Gossypol_2_24

value: Gossypol


title: lncap_LNCAPPS2B_G5_BKM120_0.5_24


title: lncap_LNCAPPS2B_E5_Selumetinib_10_24

value: Selumetinib


title: lncap_LNCAPPS2B_C5_FK866_8.5_24


title: lncap_LNCAPPS2B_D5_Saracatinib_1_24

value: Saracatinib


title: lncap_LNCAPPS2B_A5_Sonidegib_8_24

value: Sonidegib


title: lncap_LNCAPPS2B_F5_AZD2014_0.17_24

value: LNCaP


title: lncap_LNCAPPS2B_G4_Rosiglitazone_2_24

value: Rosiglitazone


title: lncap_LNCAPPS2B_H4_Omacetaxine_0.01_24

value: Omacetaxine


title: lncap_LNCAPPS2B_E4_Clarithromycin_1_24

value: Clarithromycin


title: lncap_LNCAPPS2B_F4_Bosentan_1_24

value: Bosentan


title: lncap_LNCAPPS2B_E6_UNTREATED_0_24

value: UNTREATED

value: ATCC


title: lncap_LNCAPPS2B_C4_Floxuridine_10_24

value: Floxuridine


title: lncap_LNCAPPS2B_D4_Cyclophosphamide_10_24

value: Cyclophosphamide

value: male


title: lncap_LNCAPPS2B_B4_Bicalutamide_10_24

value: Bicalutamide


title: lncap_LNCAPPS2B_A4_Finasteride_5.5_24

value: Finasteride


title: lncap_LNCAPPS2B_F3_Gefitinib_0.5_24

value: Gefitinib


title: lncap_LNCAPPS2B_E3_Dacarbazine_10_24

value: Dacarbazine


title: lncap_LNCAPPS2B_C3_Azathioprine_10_24

value: Azathioprine


title: lncap_LNCAPPS2B_D3_Prednisone_1_24

value: Prednisone


title: lncap_LNCAPPS2B_H3_Altretamine_10_24

value: Altretamine


title: lncap_LNCAPPS2B_B3_Albendazole_2_24

value: Albendazole

value: LNCaP


title: lncap_LNCAPPS2B_H2_Thalidomide_8.5_24

value: Thalidomide


title: lncap_LNCAPPS2B_A3_Bosutinib_0.5_24

value: Bosutinib


title: lncap_LNCAPPS2B_G3_Leucovorin_2_24

value: Leucovorin


title: lncap_LNCAPPS2B_F2_Oxaliplatin_2.5_24

value: Oxaliplatin


title: lncap_LNCAPPS2B_E2_Arsenic_0.5_24

value: Arsenic

value: ATCC


title: lncap_LNCAPPS2B_C2_UNTREATED_0_24

value: UNTREATED


title: lncap_LNCAPPS2B_D2_UNTREATED_0_24

value: male


title: lncap_LNCAPPS2B_B2_DMSO_0_24

value: DMSO


title: lncap_LNCAPPS2B_B5_AUY922_1_24


title: lncap_LNCAPPS2B_G2_Fludarabine_3_24

value: Fludarabine


title: lncap_LNCAPPS2B_G1_Pipobroman_10_24

value: Pipobroman


title: lncap_LNCAPPS2B_A2_DMSO_0_24


title: lncap_LNCAPPS2B_H1_Carmustine_1.5_24

value: Carmustine


title: lncap_LNCAPPS2B_F1_Azacitidine_0.5_24

value: Azacitidine


title: lncap_LNCAPPS2B_E1_Amsacrine_0.5_24

value: Amsacrine


title: lncap_LNCAPPS2B_D1_Hydroxyurea_10_24

value: Hydroxyurea


title: lncap_LNCAPPS2B_C1_Teniposide_1_24

value: Teniposide


title: lncap_LNCAPPS2B_B1_Melphalan_1_24

value: Melphalan

value: LNCaP


title: lncap_LNCAPPS2A_H12_Dactinomycin_0.00175_24

value: Dactinomycin


title: lncap_LNCAPPS2B_A1_Mechlorethamine_1_24

value: Mechlorethamine


title: lncap_LNCAPPS2A_G12_Erlotinib_0.01_24

value: Erlotinib


title: lncap_LNCAPPS2A_F12_Idarubicin_0.02_24

value: Idarubicin


title: lncap_LNCAPPS2A_E12_Vorinostat_0.28_24

value: Vorinostat

value: ATCC


title: lncap_LNCAPPS2A_B12_Tofacitinib_0.305_24

value: Tofacitinib

value: male


title: lncap_LNCAPPS2A_H11_UNTREATED_0_24

value: UNTREATED


title: lncap_LNCAPPS2A_A12_Busulfan_0.295_24

value: Busulfan


title: lncap_LNCAPPS2A_E11_DMSO_0_24

value: DMSO


title: lncap_LNCAPPS2A_C11_Disulfiram_0.01_24

value: Disulfiram


title: lncap_LNCAPPS2A_F11_DMSO_0_24


title: lncap_LNCAPPS2A_B11_Axitinib_0.14_24

value: Axitinib


title: lncap_LNCAPPS2A_F10_YM155_0.07_24


title: lncap_LNCAPPS2A_C10_SNX2112_0.285_24


title: lncap_LNCAPPS2A_A11_Rigosertib_0.1_24

value: Rigosertib


title: lncap_LNCAPPS2A_A10_MK1775_0.24_24


title: lncap_LNCAPPS2A_D10_GDC0941_0.5_24


title: lncap_LNCAPPS2A_B10_SB743921_0.13_24


title: lncap_LNCAPPS2A_E10_KX2391_0.2_24


title: lncap_LNCAPPS2A_G9_Epigallocatechin_0.5_24

value: Epigallocatechin


title: lncap_LNCAPPS2A_G11_UNTREATED_0_24


title: lncap_LNCAPPS2A_H10_Flavopiridol_0.055_24

value: Flavopiridol


title: lncap_LNCAPPS2A_E9_Dinaciclib_0.015_24

value: Dinaciclib

value: LNCaP


title: lncap_LNCAPPS2A_D9_Alisertib_10_24

value: Alisertib


title: lncap_LNCAPPS2A_B9_MK2206_0.01_24


title: lncap_LNCAPPS2A_F9_Neratinib_0.225_24

value: Neratinib


title: lncap_LNCAPPS2A_C12_Thiotepa_0.02_24

value: Thiotepa


title: lncap_LNCAPPS2A_D12_Daunorubicin_0.045_24

value: Daunorubicin


title: lncap_LNCAPPS2A_D11_Megestrol_0.045_24

value: Megestrol

value: ATCC


title: lncap_LNCAPPS2A_G10_Entinostat_0.5_24

value: Entinostat

value: male


title: lncap_LNCAPPS2A_D8_JNJ26854165_0.155_24


title: lncap_LNCAPPS2A_E8_BGJ398_8_24


title: lncap_LNCAPPS2A_C9_Foretinib_2.5_24

value: Foretinib


title: lncap_LNCAPPS2A_H8_HMN214_0.5_24


title: lncap_LNCAPPS2A_A9_Amuvatinib_0.02_24

value: Amuvatinib


title: lncap_LNCAPPS2A_F8_Linifanib_1_24

value: Linifanib


title: lncap_LNCAPPS2A_C8_KW2449_8_24


title: lncap_LNCAPPS2A_G8_Tivantinib_1.5_24

value: Tivantinib


title: lncap_LNCAPPS2A_B8_Cinacalcet_2_24

value: Cinacalcet


title: lncap_LNCAPPS2A_A8_BI2536_1_24


title: lncap_LNCAPPS2A_H7_GSK461364_0.5_24


title: lncap_LNCAPPS2A_F7_PD0325901_0.5_24


title: lncap_LNCAPPS2A_G7_Brivanib_10_24

value: Brivanib


title: lncap_LNCAPPS2A_E7_PKC412_10_24


title: lncap_LNCAPPS2A_D7_Bafetinib_7_24

value: Bafetinib


title: lncap_LNCAPPS2A_B7_Alpelisib_0.37_24

value: Alpelisib


title: lncap_LNCAPPS2A_A7_AZD5363_0.035_24

value: LNCaP


title: lncap_LNCAPPS2A_C7_Motesanib_1_24

value: Motesanib


title: lncap_LNCAPPS2A_G6_AZD1480_0.13_24


title: lncap_LNCAPPS2A_F6_UNTREATED_0_24

value: UNTREATED


title: lncap_LNCAPPS2A_E6_UNTREATED_0_24


title: lncap_LNCAPPS2A_D6_DMSO_0_24

value: DMSO


title: lncap_LNCAPPS2A_B6_Bardoxolone Methyl_1_24

value: Bardoxolone Methyl


title: lncap_LNCAPPS2A_C6_DMSO_0_24


title: lncap_LNCAPPS2A_H5_Gossypol_2_24

value: Gossypol


title: lncap_LNCAPPS2A_F5_AZD2014_0.17_24

value: ATCC


title: lncap_LNCAPPS2A_D5_Saracatinib_1_24

value: Saracatinib


title: lncap_LNCAPPS2A_G5_BKM120_0.5_24

value: male


title: lncap_LNCAPPS2A_A6_Elesclomol_0.02_24

value: Elesclomol


title: lncap_LNCAPPS2A_E5_Selumetinib_10_24

value: Selumetinib


title: lncap_LNCAPPS2A_C5_FK866_8.5_24


title: lncap_LNCAPPS2A_F4_Bosentan_1_24

value: Bosentan


title: lncap_LNCAPPS2A_B5_AUY922_1_24


title: lncap_LNCAPPS2A_H4_Omacetaxine_0.01_24

value: Omacetaxine


title: lncap_LNCAPPS2A_G4_Rosiglitazone_2_24

value: Rosiglitazone


title: lncap_LNCAPPS2A_A5_Sonidegib_8_24

value: Sonidegib


title: lncap_LNCAPPS2A_C4_Floxuridine_10_24

value: Floxuridine


title: lncap_LNCAPPS2A_D4_Cyclophosphamide_10_24

value: Cyclophosphamide


title: lncap_LNCAPPS2A_D3_Prednisone_1_24

value: Prednisone

value: LNCaP


title: lncap_LNCAPPS2A_E3_Dacarbazine_10_24

value: Dacarbazine


title: lncap_LNCAPPS2A_F3_Gefitinib_0.5_24

value: Gefitinib


title: lncap_LNCAPPS2A_G3_Leucovorin_2_24

value: Leucovorin


title: lncap_LNCAPPS2A_H3_Altretamine_10_24

value: Altretamine


title: lncap_LNCAPPS2A_B3_Albendazole_2_24

value: Albendazole

value: ATCC


title: lncap_LNCAPPS2A_C3_Azathioprine_10_24

value: Azathioprine

value: male


title: lncap_LNCAPPS2A_A3_Bosutinib_0.5_24

value: Bosutinib


title: lncap_LNCAPPS2A_H2_Thalidomide_8.5_24

value: Thalidomide


title: lncap_LNCAPPS2A_F2_Oxaliplatin_2.5_24

value: Oxaliplatin


title: lncap_LNCAPPS2A_E2_Arsenic_0.5_24

value: Arsenic


title: lncap_LNCAPPS2A_B2_DMSO_0_24

value: DMSO


title: lncap_LNCAPPS2A_H9_Obatoclax Mesylate_0.335_24

value: Obatoclax Mesylate


title: lncap_LNCAPPS2A_H1_Carmustine_1.5_24

value: Carmustine


title: lncap_LNCAPPS2A_G2_Fludarabine_3_24

value: Fludarabine


title: lncap_LNCAPPS2A_A2_DMSO_0_24

value: LNCaP


title: lncap_LNCAPPS2A_D2_UNTREATED_0_24

value: UNTREATED


title: lncap_LNCAPPS2A_D1_Hydroxyurea_10_24

value: Hydroxyurea


title: lncap_LNCAPPS2A_E4_Clarithromycin_1_24

value: Clarithromycin


title: lncap_LNCAPPS2A_C1_Teniposide_1_24

value: Teniposide


title: lncap_LNCAPPS2A_G1_Pipobroman_10_24

value: Pipobroman


title: lncap_LNCAPPS2A_A4_Finasteride_5.5_24

value: Finasteride

value: ATCC


title: lncap_LNCAPPS2A_C2_UNTREATED_0_24

value: male


title: lncap_LNCAPPS2A_B1_Melphalan_1_24

value: Melphalan


title: lncap_LNCAPPS1B_G12_Ponatinib_0.135_24

value: Ponatinib


title: lncap_LNCAPPS1B_H12_Epirubicin_0.16_24

value: Epirubicin


title: lncap_LNCAPPS2A_A1_Mechlorethamine_1_24

value: Mechlorethamine


title: lncap_LNCAPPS2A_E1_Amsacrine_0.5_24

value: Amsacrine


title: lncap_LNCAPPS2A_H6_Navitoclax_0.5_24

value: Navitoclax


title: lncap_LNCAPPS1B_F12_Pomalidomide_0.21_24

value: Pomalidomide


title: lncap_LNCAPPS1B_H11_UNTREATED_0_24


title: lncap_LNCAPPS1B_E12_Cabazitaxel_0.27_24

value: Cabazitaxel


title: lncap_LNCAPPS2A_B4_Bicalutamide_10_24

value: Bicalutamide

value: LNCaP


title: lncap_LNCAPPS1B_C12_Paclitaxel_6.5_24

value: Paclitaxel


title: lncap_LNCAPPS1B_G11_UNTREATED_0_24

value: UNTREATED


title: lncap_LNCAPPS1B_B12_Fluorouracil_10_24

value: Fluorouracil


title: lncap_LNCAPPS1B_F11_DMSO_0_24

value: DMSO


title: lncap_LNCAPPS1B_A12_Sorafenib_4.5_24

value: Sorafenib


title: lncap_LNCAPPS1B_D12_Bleomycin_0.275_24

value: Bleomycin

value: ATCC


title: lncap_LNCAPPS1B_D11_Sunitinib_0.045_24

value: Sunitinib

value: male


title: lncap_LNCAPPS1B_C11_Afatinib_0.185_24

value: Afatinib


title: lncap_LNCAPPS1B_B11_Pralatrexate_10_24

value: Pralatrexate


title: lncap_LNCAPPS1B_H10_Bortezomib_0.055_24

value: Bortezomib


title: lncap_LNCAPPS2A_F1_Azacitidine_0.5_24

value: Azacitidine


title: lncap_LNCAPPS1B_E11_DMSO_0_24


title: lncap_LNCAPPS1B_A11_Dasatinib_0.345_24

value: Dasatinib


title: Donor 4, CD8-positive gd T cells

city: Chicago

first: Roshni

last: Roy Chowdhury

address: 924 E 57th Street

institute: University of Chicago

data_processing:
Raw Illumina sequences were checked for quality using FastQC version 0.11.8 (Babraham Bioinformatics) and aligned to the GRCh38/hg38 Human genome (UCSC Genome Browser) using star RNASeq aligner version 2.5.4b
Resulting alignments were processed with the feature Counts software version 2.0.0 (subread) to obtain raw counts for each gene

source_name: gamma delta T cells

extract_protocol:
RNA was extracted using TRIZOL.
cDNA was generated using the SMART-Seq v4 Ultra Low Input RNA Kit (Takara)
The amplified cDNA was fragmented, and libraries were made using the Illumina Nextera-XT kit, following manufacturer’s instructions

tag: cell type

value: gamma delta T cells


title: Donor 5, CD8-positive gd T cells


title: Donor 2, CD8-positive gd T cells


title: Donor 3, CD8-positive gd T cells


title: Donor 3, CD8-negative gd T cells


title: Donor 5, CD8-negative gd T cells


title: Donor 1, CD8-negative gd T cells


title: lncap_LNCAPPS5B_H11_UNTREATED_0_24


title: Donor 2, CD8-negative gd T cells


title: lncap_LNCAPPS5B_H9_Piperlongumine_1_24

value: Piperlongumine


title: Donor 4, CD8-negative gd T cells


title: lncap_LNCAPPS5B_H7_Calmidazolium chloride_1.5_24

value: Calmidazolium chloride

value: LNCaP


title: lncap_LNCAPPS5B_H8_Dihydroouabain_2_24

value: Dihydroouabain


title: lncap_LNCAPPS5B_H6_Bay 11-7821_0.5_24


title: lncap_LNCAPPS5B_H10_PD-184161_3.5_24


title: lncap_LNCAPPS5B_H4_Scriptaid_0.5_24

value: Scriptaid


title: lncap_LNCAPPS5B_H2_Ro 106-9920_1.5_24


title: lncap_LNCAPPS5B_H1_SB 216641 hydrochloride_3.5_24

value: SB 216641 hydrochloride


title: lncap_LNCAPPS5B_H3_NNC 05-2090 hydrochloride_3.5_24

value: NNC 05-2090 hydrochloride


title: lncap_LNCAPPS5B_H5_Ryuvidine_0.18_24

value: Ryuvidine


title: lncap_LNCAPPS5B_G12_Thapsigargin_0.01_24

value: Thapsigargin

value: ATCC


title: lncap_LNCAPPS5B_G10_Podophyllotoxin_0.02_24

value: Podophyllotoxin

value: male


title: lncap_LNCAPPS5B_G11_UNTREATED_0_24

value: UNTREATED


title: lncap_LNCAPPS5B_G6_Etonitazenyl isothiocyanate_4_24

value: Etonitazenyl isothiocyanate


title: lncap_LNCAPPS5B_G7_Bay 11-7085_3_24


title: Donor 1, CD8-positive gd T cells


title: lncap_LNCAPPS5B_G8_BNTX maleate salt hydrate_0.5_24

value: BNTX maleate salt hydrate


title: lncap_LNCAPPS5B_F12_Tetraethylthiuram disulfide_0.11_24

value: Tetraethylthiuram disulfide


title: lncap_LNCAPPS5B_G2_FIT_4_24

value: FIT


title: lncap_LNCAPPS5B_G4_AT 101_1.5_24


title: lncap_LNCAPPS5B_G3_PHA 665752_4.5_24


title: lncap_LNCAPPS5B_F7_CP-100356 monohydrochloride_2_24

value: CP-100356 monohydrochloride


title: lncap_LNCAPPS5B_F11_DMSO_0_24

value: DMSO


title: lncap_LNCAPPS5B_F10_beta-Lapachone_1_24

value: beta-Lapachone

value: LNCaP


title: lncap_LNCAPPS5B_F9_Emetine dihydrochloride hydrate_0.035_24

value: Emetine dihydrochloride hydrate


title: lncap_LNCAPPS5B_G5_JK 184_0.09_24


title: lncap_LNCAPPS5B_F8_Brefeldin A_0.05_24

value: Brefeldin A


title: lncap_LNCAPPS5B_F5_SN 38_0.075_24

value: SN 38


title: lncap_LNCAPPS5B_E12_Vincristine_0.025_24

value: Vincristine


title: lncap_LNCAPPS5B_G1_RS 17053 hydrochloride_2_24

value: RS 17053 hydrochloride


title: lncap_LNCAPPS5B_G9_AC-93253 iodide_0.03_24

value: AC-93253 iodide

value: ATCC


title: lncap_LNCAPPS5B_F3_JTC 801_0.5_24

value: JTC 801

value: male


title: lncap_LNCAPPS5B_F2_GR 127935 hydrochloride_2.5_24

value: GR 127935 hydrochloride


title: lncap_LNCAPPS5B_H12_Phorbol 12-myristate 13-acetate_0.0009_24

value: Phorbol 12-myristate 13-acetate


title: lncap_LNCAPPS5B_E10_Niclosamide_1_24

value: Niclosamide


title: lncap_LNCAPPS5B_E9_Diphenyleneiodonium chloride_0.04_24

value: Diphenyleneiodonium chloride


title: lncap_LNCAPPS5B_F1_Metaphit_2.5_24

value: Metaphit


title: lncap_LNCAPPS5B_F4_BIBU 1361 dihydrochloride_1.5_24

value: BIBU 1361 dihydrochloride


title: lncap_LNCAPPS5B_E6_UNTREATED_0_24

value: UNTREATED


title: lncap_LNCAPPS5B_E8_Calcimycin_0.5_24

value: Calcimycin

value: LNCaP


title: lncap_LNCAPPS5B_E7_Cantharidin_1_24

value: Cantharidin


title: lncap_LNCAPPS5B_E4_SNAP 5089_3_24

value: SNAP 5089


title: lncap_LNCAPPS5B_E3_ER 27319 maleate_0.5_24

value: ER 27319 maleate


title: lncap_LNCAPPS5B_E5_Astemizole_2_24

value: Astemizole


title: lncap_LNCAPPS5B_E2_WIN 64338 hydrochloride_2_24

value: WIN 64338 hydrochloride


title: lncap_LNCAPPS5B_F6_UNTREATED_0_24

value: ATCC


title: lncap_LNCAPPS5B_D9_(S)-(+)-Camptothecin_0.035_24

value: (S)-(+)-Camptothecin


title: lncap_LNCAPPS5B_E11_DMSO_0_24

value: DMSO

value: male


title: lncap_LNCAPPS5B_D8_Benserazide hydrochloride_4.5_24

value: Benserazide hydrochloride


title: lncap_LNCAPPS5B_D7_Chelerythrine chloride_1_24

value: Chelerythrine chloride


title: lncap_LNCAPPS5B_E1_Pyrrolidinedithiocarbamate ammonium_1_24

value: Pyrrolidinedithiocarbamate ammonium


title: lncap_LNCAPPS5B_D11_Terfenadine_2_24

value: Terfenadine


title: lncap_LNCAPPS5B_D3_Ro 31-8220 mesylate_0.5_24

value: Ro 31-8220 mesylate


title: lncap_LNCAPPS5B_D6_DMSO_0_24


title: lncap_LNCAPPS5B_D2_UNTREATED_0_24

value: UNTREATED


title: lncap_LNCAPPS5B_D4_IMD 0354_2_24


title: lncap_LNCAPPS5B_D12_CP-31398 dihydrochloride hydrate_2_24

value: CP-31398 dihydrochloride hydrate


title: lncap_LNCAPPS5B_C11_Quinacrine dihydrochloride_1.5_24

value: Quinacrine dihydrochloride

value: LNCaP


title: lncap_LNCAPPS5B_C10_Ivermectin_2_24

value: Ivermectin


title: lncap_LNCAPPS5B_C12_Sanguinarine chloride_0.5_24

value: Sanguinarine chloride


title: lncap_LNCAPPS5B_C9_2_3-Dimethoxy-1_4-naphthoquinone_3-Dimethoxy-1_4-naphthoquinone_0.5_24


title: lncap_LNCAPPS5B_D5_NSC632839_2_24


title: lncap_LNCAPPS5B_C7_Anisomycin_0.06_24

value: Anisomycin


title: lncap_LNCAPPS5B_C6_DMSO_0_24


title: lncap_LNCAPPS5B_C4_Bax channel blocker_1.5_24

value: Bax channel blocker


title: lncap_LNCAPPS5B_D1_Tetrindole mesylate_3_24

value: Tetrindole mesylate

value: ATCC


title: lncap_LNCAPPS5B_C3_ZK 93423_2.5_24


title: lncap_LNCAPPS5B_C1_IPAG_0.5_24

value: IPAG


title: lncap_LNCAPPS5B_B12_Wiskostatin_2_24

value: Wiskostatin

value: male


title: lncap_LNCAPPS5B_B11_Stattic_1.5_24

value: Stattic


title: lncap_LNCAPPS5B_D10_Parthenolide_0.5_24

value: Parthenolide


title: lncap_LNCAPPS5B_B10_L-703_606 oxalate salt hydrate_2.5_24

value: L-703_606 oxalate salt hydrate


title: lncap_LNCAPPS5B_B9_NSC 95397_1_24


title: lncap_LNCAPPS5B_B8_CGP-74514A hydrochloride_0.5_24

value: CGP-74514A hydrochloride


title: lncap_LNCAPPS5B_B7_(R)-CR8_0.23_24


title: lncap_LNCAPPS5B_B4_Lylamine hydrochloride_1.5_24

value: Lylamine hydrochloride


title: lncap_LNCAPPS5B_C8_Bromoacetyl alprenolol menthane_2.5_24

value: Bromoacetyl alprenolol menthane


title: lncap_LNCAPPS5B_B3_NSC 663284_1.5_24


title: lncap_LNCAPPS5B_A11_Auranofin_0.5_24

value: Auranofin


title: lncap_LNCAPPS5B_A7_SR 33805 oxalate_2.5_24

value: SR 33805 oxalate

value: LNCaP


title: lncap_LNCAPPS5B_C5_CGK 733_3_24

value: CGK 733


title: lncap_LNCAPPS5B_A9_Ellipticine_1_24

value: Ellipticine


title: lncap_LNCAPPS5B_A5_Mibefradil dihydrochloride_2.5_24

value: Mibefradil dihydrochloride


title: lncap_LNCAPPS5B_A4_IKK 16_2_24

value: IKK 16


title: lncap_LNCAPPS5B_B1_HEAT hydrochloride_1.5_24

value: HEAT hydrochloride

value: ATCC


title: lncap_LNCAPPS5B_A3_(R)-(-)-Niguldipine hydrochloride_2.5_24

value: (R)-(-)-Niguldipine hydrochloride


title: lncap_LNCAPPS5B_C2_UNTREATED_0_24

value: UNTREATED

value: male


title: lncap_LNCAPPS5B_A1_3'-Fluorobenzylspiperone maleate_3.5_24

value: 3'-Fluorobenzylspiperone maleate


title: lncap_LNCAPPS5B_A8_Z-L-Phe chloromethyl ketone_1.5_24

value: Z-L-Phe chloromethyl ketone


title: lncap_LNCAPPS5B_A2_DMSO_0_24

value: DMSO


title: lncap_LNCAPPS5A_H10_PD-184161_3.5_24


title: lncap_LNCAPPS5A_H9_Piperlongumine_1_24

value: Piperlongumine


title: lncap_LNCAPPS5A_H8_Dihydroouabain_2_24

value: Dihydroouabain


title: lncap_LNCAPPS5B_A6_SU 3327_1.5_24


title: lncap_LNCAPPS5A_H7_Calmidazolium chloride_1.5_24

value: Calmidazolium chloride


title: lncap_LNCAPPS5B_B5_CGP 71683 hydrochloride_5_24

value: CGP 71683 hydrochloride


title: lncap_LNCAPPS5B_B2_DMSO_0_24

value: LNCaP


title: lncap_LNCAPPS5B_B6_DIPPA hydrochloride_2_24

value: DIPPA hydrochloride


title: lncap_LNCAPPS5B_A12_PAC-1_2_24


title: lncap_LNCAPPS5B_A10_NNC 55-0396_4.5_24


title: lncap_LNCAPPS1B_F10_Docetaxel_6_24

value: Docetaxel


title: lncap_LNCAPPS1B_D10_Fulvestrant_0.03_24

value: Fulvestrant


title: lncap_LNCAPPS1B_G10_Panobinostat_0.005_24

value: Panobinostat


title: lncap_LNCAPPS1B_E10_Vinorelbine_0.01_24

value: Vinorelbine


title: lncap_LNCAPPS1B_C10_Leuprolide_0.075_24

value: Leuprolide

value: ATCC


title: lncap_LNCAPPS1B_A10_Carfilzomib_0.01_24

value: Carfilzomib


title: lncap_LNCAPPS1B_G9_Ixazomib_0.155_24

value: Ixazomib

value: male


title: lncap_LNCAPPS1B_B10_Ibrutinib_0.35_24

value: Ibrutinib


title: lncap_LNCAPPS5A_H11_UNTREATED_0_24

value: UNTREATED


title: lncap_LNCAPPS1B_A9_Toremifene_1.5_24

value: Toremifene


title: lncap_LNCAPPS1B_D9_Ruxolitinib_10_24

value: Ruxolitinib


title: lncap_LNCAPPS1B_H9_Trifluridine_10_24

value: Trifluridine


title: lncap_LNCAPPS5A_H12_Phorbol 12-myristate 13-acetate_0.0009_24

value: Phorbol 12-myristate 13-acetate


title: lncap_LNCAPPS1B_H8_Temozolomide_10_24

value: Temozolomide

value: LNCaP


title: lncap_LNCAPPS1B_G8_Lenvatinib_0.5_24

value: Lenvatinib


title: lncap_LNCAPPS1B_E8_Raloxifene_0.01_24

value: Raloxifene


title: lncap_LNCAPPS1B_D8_Ceritinib_1_24

value: Ceritinib


title: lncap_LNCAPPS1B_F8_Cytarabine_10_24

value: Cytarabine


title: lncap_LNCAPPS1B_B9_Belinostat_0.5_24

value: Belinostat


title: lncap_LNCAPPS1B_C8_Thioguanine_1_24

value: Thioguanine

value: ATCC


title: lncap_LNCAPPS1B_H7_Exemestane_1_24

value: Exemestane


title: lncap_LNCAPPS1B_A8_Vinblastine_0.165_24

value: Vinblastine

value: male


title: lncap_LNCAPPS1B_G7_Methotrexate_10_24

value: Methotrexate


title: lncap_LNCAPPS1B_F7_Etoposide_10_24

value: Etoposide


title: lncap_LNCAPPS1B_C7_Doxorubicin_0.03_24

value: Doxorubicin


title: lncap_LNCAPPS1B_B8_Tretinoin_2_24

value: Tretinoin


title: lncap_LNCAPPS1B_D7_Gemcitabine_4.5_24

value: Gemcitabine


title: lncap_LNCAPPS1B_E7_Mercaptopurine_1_24

value: Mercaptopurine


title: lncap_LNCAPPS1B_A7_Mitoxantrone_0.03_24

value: Mitoxantrone

value: LNCaP


title: lncap_LNCAPPS1B_B7_Mitomycin_0.5_24

value: Mitomycin


title: lncap_LNCAPPS1B_H6_Ifosfamide_10_24

value: Ifosfamide


title: lncap_LNCAPPS1B_F9_Trametinib_0.035_24

value: Trametinib


title: lncap_LNCAPPS1B_C9_Osimertinib_1.5_24

value: Osimertinib


title: lncap_LNCAPPS1B_E9_Cobimetinib (GDC-0973, RG7420)_0.5_24

value: Cobimetinib (GDC-0973, RG7420)


title: lncap_LNCAPPS1B_G6_Topotecan_0.19_24

value: Topotecan

value: ATCC


title: lncap_LNCAPPS1B_A6_Imatinib_5_24

value: Imatinib


title: lncap_LNCAPPS1B_C6_DMSO_0_24

value: DMSO

value: male


title: lncap_LNCAPPS1B_H5_Tamoxifen_1_24

value: Tamoxifen


title: lncap_LNCAPPS1B_D6_DMSO_0_24


title: lncap_LNCAPPS1B_E5_Mithramycin_0.18_24

value: Mithramycin


title: lncap_LNCAPPS5A_H6_Bay 11-7821_0.5_24


title: lncap_LNCAPPS1B_B5_Crizotinib_0.19_24

value: Crizotinib


title: lncap_LNCAPPS1B_F5_Vandetanib_0.125_24

value: Vandetanib


title: lncap_LNCAPPS1B_D5_Olaparib_2.5_24

value: Olaparib


title: lncap_LNCAPPS1B_C5_Everolimus_1_24

value: Everolimus


title: lncap_LNCAPPS1B_A5_Ixabepilone_0.0007_24

value: Ixabepilone

value: LNCaP


title: lncap_LNCAPPS1B_G4_Pentostatin_1_24

value: Pentostatin


title: lncap_LNCAPPS1B_H4_Estramustine_3.5_24

value: Estramustine


title: lncap_LNCAPPS1B_E4_Dabrafenib_1.5_24

value: Dabrafenib


title: lncap_LNCAPPS1B_F4_Pazopanib_7.5_24

value: Pazopanib


title: lncap_LNCAPPS1B_D4_Procarbazine_2_24

value: Procarbazine


title: lncap_LNCAPPS1B_B4_Carboplatin_10_24

value: Carboplatin

value: ATCC


title: lncap_LNCAPPS1B_A4_Cisplatin_6_24

value: Cisplatin


title: lncap_LNCAPPS1B_H3_Abiraterone_10_24

value: Abiraterone

value: male


title: lncap_LNCAPPS1B_E3_Capecitabine_10_24

value: Capecitabine


title: lncap_LNCAPPS1B_F6_UNTREATED_0_24

value: UNTREATED


title: lncap_LNCAPPS1B_C4_Lomustine_7_24

value: Lomustine


title: lncap_LNCAPPS1B_F3_Mitotane_10_24

value: Mitotane


title: lncap_LNCAPPS1B_D3_Nelarabine_10_24

value: Nelarabine


title: lncap_LNCAPPS1B_G5_Nilotinib_2_24

value: Nilotinib


title: lncap_LNCAPPS1B_B3_Vemurafenib_10_24

value: Vemurafenib

value: LNCaP


title: lncap_LNCAPPS1B_A3_Bendamustine_10_24

value: Bendamustine


title: lncap_LNCAPPS1B_C3_Cabozantinib_1_24

value: Cabozantinib


title: lncap_LNCAPPS1B_B6_Bexarotene_1.5_24

value: Bexarotene


title: lncap_LNCAPPS1B_F2_Letrozole_1.5_24

value: Letrozole


title: lncap_LNCAPPS1B_E6_UNTREATED_0_24


title: lncap_LNCAPPS1B_G2_Vismodegib_10_24

value: Vismodegib


title: lncap_LNCAPPS1B_E2_Cladribine_0.5_24

value: Cladribine

value: ATCC


title: lncap_LNCAPPS1B_D2_UNTREATED_0_24


title: lncap_LNCAPPS1B_C2_UNTREATED_0_24


title: lncap_LNCAPPS1B_A2_DMSO_0_24

value: DMSO


title: lncap_LNCAPPS1B_B2_DMSO_0_24

value: male


title: lncap_LNCAPPS1B_H1_Anastrozole_10_24

value: Anastrozole


title: lncap_LNCAPPS1B_F1_Irinotecan_2.5_24

value: Irinotecan


title: lncap_LNCAPPS1B_G3_Temsirolimus_1_24

value: Temsirolimus


title: lncap_LNCAPPS1B_B1_Pemetrexed_10_24

value: Pemetrexed


title: lncap_LNCAPPS1B_C1_Clofarabine_1.5_24

value: Clofarabine


title: lncap_LNCAPPS1B_A1_Lapatinib_4_24

value: Lapatinib


title: lncap_LNCAPPS1A_C12_Paclitaxel_6.5_24

value: Paclitaxel


title: lncap_LNCAPPS1A_F12_Pomalidomide_0.21_24

value: Pomalidomide

value: LNCaP


title: lncap_LNCAPPS1B_D1_Lenalidomide_1.5_24

value: Lenalidomide


title: lncap_LNCAPPS1A_H12_Epirubicin_0.16_24

value: Epirubicin


title: lncap_LNCAPPS1A_E12_Cabazitaxel_0.27_24

value: Cabazitaxel


title: lncap_LNCAPPS1B_H2_Decitabine_0.5_24

value: Decitabine


title: lncap_LNCAPPS1A_G11_UNTREATED_0_24

value: UNTREATED


title: lncap_LNCAPPS1A_H11_UNTREATED_0_24

value: ATCC


title: lncap_LNCAPPS1A_D11_Sunitinib_0.045_24

value: Sunitinib


title: lncap_LNCAPPS1A_E11_DMSO_0_24

value: DMSO

value: male


title: lncap_LNCAPPS1A_F11_DMSO_0_24


title: lncap_LNCAPPS1A_B12_Fluorouracil_10_24

value: Fluorouracil


title: lncap_LNCAPPS1A_B11_Pralatrexate_10_24

value: Pralatrexate


title: lncap_LNCAPPS1A_C11_Afatinib_0.185_24

value: Afatinib


title: lncap_LNCAPPS1A_G10_Panobinostat_0.005_24

value: Panobinostat


title: lncap_LNCAPPS1A_F10_Docetaxel_6_24

value: Docetaxel


title: lncap_LNCAPPS1A_H10_Bortezomib_0.055_24

value: Bortezomib


title: lncap_LNCAPPS1B_E1_Regorafenib_5_24

value: Regorafenib


title: lncap_LNCAPPS1A_D10_Fulvestrant_0.03_24

value: Fulvestrant

value: LNCaP


title: lncap_LNCAPPS1A_C10_Leuprolide_0.075_24

value: Leuprolide


title: lncap_LNCAPPS1B_G1_Enzalutamide_10_24

value: Enzalutamide


title: lncap_LNCAPPS1A_D12_Bleomycin_0.275_24

value: Bleomycin


title: lncap_LNCAPPS1A_A12_Sorafenib_4.5_24

value: Sorafenib


title: lncap_LNCAPPS1A_B10_Ibrutinib_0.35_24

value: Ibrutinib

value: ATCC


title: lncap_LNCAPPS1A_A10_Carfilzomib_0.01_24

value: Carfilzomib


title: lncap_LNCAPPS1A_H9_Trifluridine_10_24

value: Trifluridine

value: male


title: lncap_LNCAPPS1A_G9_Ixazomib_0.155_24

value: Ixazomib


title: lncap_LNCAPPS1A_F9_Trametinib_0.035_24

value: Trametinib


title: lncap_LNCAPPS1A_C9_Osimertinib_1.5_24

value: Osimertinib


title: lncap_LNCAPPS1A_E9_Cobimetinib (GDC-0973, RG7420)_0.5_24

value: Cobimetinib (GDC-0973, RG7420)


title: lncap_LNCAPPS1A_G12_Ponatinib_0.135_24

value: Ponatinib


title: lncap_LNCAPPS1A_D9_Ruxolitinib_10_24

value: Ruxolitinib


title: lncap_LNCAPPS1A_B9_Belinostat_0.5_24

value: Belinostat


title: lncap_LNCAPPS1A_A9_Toremifene_1.5_24

value: Toremifene

value: LNCaP


title: lncap_LNCAPPS1A_H8_Temozolomide_10_24

value: Temozolomide


title: lncap_LNCAPPS1A_G8_Lenvatinib_0.5_24

value: Lenvatinib


title: lncap_LNCAPPS1A_D8_Ceritinib_1_24

value: Ceritinib


title: lncap_LNCAPPS1A_A11_Dasatinib_0.345_24

value: Dasatinib


title: lncap_LNCAPPS1A_F8_Cytarabine_10_24

value: Cytarabine

value: ATCC


title: lncap_LNCAPPS1A_A8_Vinblastine_0.165_24

value: Vinblastine


title: lncap_LNCAPPS1A_E10_Vinorelbine_0.01_24

value: Vinorelbine

value: male


title: lncap_LNCAPPS1A_F7_Etoposide_10_24

value: Etoposide


title: lncap_LNCAPPS1A_E8_Raloxifene_0.01_24

value: Raloxifene


title: lncap_LNCAPPS1A_H7_Exemestane_1_24

value: Exemestane


title: lncap_LNCAPPS1A_C8_Thioguanine_1_24

value: Thioguanine


title: lncap_LNCAPPS1A_G7_Methotrexate_10_24

value: Methotrexate


title: lncap_LNCAPPS1A_B8_Tretinoin_2_24

value: Tretinoin


title: lncap_LNCAPPS1A_H6_Ifosfamide_10_24

value: Ifosfamide


title: lncap_LNCAPPS1A_C7_Doxorubicin_0.03_24

value: Doxorubicin

value: LNCaP


title: lncap_LNCAPPS1A_G6_Topotecan_0.19_24

value: Topotecan


title: lncap_LNCAPPS1A_B7_Mitomycin_0.5_24

value: Mitomycin


title: lncap_LNCAPPS1A_E7_Mercaptopurine_1_24

value: Mercaptopurine


title: lncap_LNCAPPS1A_D7_Gemcitabine_4.5_24

value: Gemcitabine


title: lncap_LNCAPPS1A_E6_UNTREATED_0_24

value: UNTREATED

value: ATCC


title: lncap_LNCAPPS1A_F6_UNTREATED_0_24


title: lncap_LNCAPPS1A_C6_DMSO_0_24

value: DMSO


title: lncap_LNCAPPS1A_D6_DMSO_0_24

value: male


title: lncap_LNCAPPS1A_A6_Imatinib_5_24

value: Imatinib


title: lncap_LNCAPPS1A_B6_Bexarotene_1.5_24

value: Bexarotene


title: lncap_LNCAPPS1A_H5_Tamoxifen_1_24

value: Tamoxifen


title: lncap_LNCAPPS1A_G5_Nilotinib_2_24

value: Nilotinib


title: lncap_LNCAPPS1A_F5_Vandetanib_0.125_24

value: Vandetanib


title: lncap_LNCAPPS1A_E5_Mithramycin_0.18_24

value: Mithramycin


title: lncap_LNCAPPS1A_C5_Everolimus_1_24

value: Everolimus


title: lncap_LNCAPPS1A_B5_Crizotinib_0.19_24

value: Crizotinib


title: lncap_LNCAPPS1A_D5_Olaparib_2.5_24

value: Olaparib

value: LNCaP


title: lncap_LNCAPPS1A_A5_Ixabepilone_0.0007_24

value: Ixabepilone


title: lncap_LNCAPPS1A_H4_Estramustine_3.5_24

value: Estramustine


title: lncap_LNCAPPS1A_E4_Dabrafenib_1.5_24

value: Dabrafenib


title: lncap_LNCAPPS1A_G4_Pentostatin_1_24

value: Pentostatin


title: lncap_LNCAPPS1A_F4_Pazopanib_7.5_24

value: Pazopanib

value: ATCC


title: lncap_LNCAPPS1A_A7_Mitoxantrone_0.03_24

value: Mitoxantrone

value: male


title: lncap_LNCAPPS1A_D4_Procarbazine_2_24

value: Procarbazine


title: lncap_LNCAPPS1A_H3_Abiraterone_10_24

value: Abiraterone


title: lncap_LNCAPPS1A_C4_Lomustine_7_24

value: Lomustine


title: lncap_LNCAPPS1A_A4_Cisplatin_6_24

value: Cisplatin


title: lncap_LNCAPPS1A_G3_Temsirolimus_1_24

value: Temsirolimus


title: lncap_LNCAPPS1A_F3_Mitotane_10_24

value: Mitotane


title: lncap_LNCAPPS1A_D3_Nelarabine_10_24

value: Nelarabine


title: lncap_LNCAPPS1A_B4_Carboplatin_10_24

value: Carboplatin


title: lncap_LNCAPPS1A_E3_Capecitabine_10_24

value: Capecitabine

value: LNCaP


title: lncap_LNCAPPS1A_B3_Vemurafenib_10_24

value: Vemurafenib


title: lncap_LNCAPPS1A_C3_Cabozantinib_1_24

value: Cabozantinib


title: lncap_LNCAPPS1A_E2_Cladribine_0.5_24

value: Cladribine


title: lncap_LNCAPPS1A_A3_Bendamustine_10_24

value: Bendamustine


title: lncap_LNCAPPS1A_H2_Decitabine_0.5_24

value: Decitabine

value: ATCC


title: lncap_LNCAPPS1A_C2_UNTREATED_0_24

value: UNTREATED

value: male


title: lncap_LNCAPPS1A_F2_Letrozole_1.5_24

value: Letrozole


title: lncap_LNCAPPS1A_H1_Anastrozole_10_24

value: Anastrozole


title: lncap_LNCAPPS1A_D2_UNTREATED_0_24


title: lncap_LNCAPPS1A_A2_DMSO_0_24

value: DMSO


title: lncap_LNCAPPS1A_B2_DMSO_0_24


title: lncap_LNCAPPS1A_F1_Irinotecan_2.5_24

value: Irinotecan


title: lncap_LNCAPPS1A_G1_Enzalutamide_10_24

value: Enzalutamide


title: lncap_LNCAPPS1A_E1_Regorafenib_5_24

value: Regorafenib


title: lncap_LNCAPPS1A_D1_Lenalidomide_1.5_24

value: Lenalidomide


title: lncap_LNCAPPS1A_B1_Pemetrexed_10_24

value: Pemetrexed


title: du145_DU145PS4B_H12_PP-121_1_24


title: lncap_LNCAPPS1A_A1_Lapatinib_4_24

value: Lapatinib

value: LNCaP


title: du145_DU145PS4B_H10_Dorsomorphin 2HCl_2_24

value: Dorsomorphin 2HCl


title: du145_DU145PS4B_H11_UNTREATED__24


title: lncap_LNCAPPS1A_C1_Clofarabine_1.5_24

value: Clofarabine


title: du145_DU145PS4B_H09_Tandutinib_1_24

value: Tandutinib


title: du145_DU145PS4B_H06_Picoplatin_5_24

value: Picoplatin


title: du145_DU145PS4B_H08_Danusertib_0.5_24

value: Danusertib

value: ATCC


title: du145_DU145PS4B_H03_Raltitrexed_0.02_24

value: Raltitrexed

value: male


title: du145_DU145PS4B_H02_Talampanel_1_24

value: Talampanel


title: du145_DU145PS4B_H05_Prinomastat_0.5_24

value: Prinomastat


title: du145_DU145PS4B_H01_LY2228820_0.045_24


title: du145_DU145PS4B_H04_ADH1_10_24


title: lncap_LNCAPPS1A_G2_Vismodegib_10_24

value: Vismodegib


title: du145_DU145PS4B_H07_Tirapazamine_10_24

value: Tirapazamine


title: du145_DU145PS4B_G12_Akt Inhibitor IV_0.5_24

value: Akt Inhibitor IV


title: du145_DU145PS4B_G11_UNTREATED__24

value: UNTREATED


title: du145_DU145PS4B_G07_Pilaralisib_10_24

value: Pilaralisib


title: du145_DU145PS4B_G09_Baricitinib_0.5_24

value: Baricitinib


title: du145_DU145PS4B_G10_LAQ824_0.025_24


title: du145_DU145PS4B_G06_Atrasentan_1.5_24

value: Atrasentan


title: du145_DU145PS4B_G05_Halofuginone_0.0013_24

value: Halofuginone


title: du145_DU145PS4B_G01_SCIO469_4.5_24


title: du145_DU145PS4B_G04_Pirarubicin_0.005_24

value: Pirarubicin


title: du145_DU145PS4B_G02_Galeterone_3.5_24

value: Galeterone


title: du145_DU145PS4B_F12_BI-87G3_3.5_24


title: du145_DU145PS4B_F10_NH125_0.5_24


title: du145_DU145PS4B_F07_Voreloxin_0.11_24

value: Voreloxin


title: du145_DU145PS4B_F06_UNTREATED__24


title: du145_DU145PS4B_F09_Oprozomib_0.02_24

value: Oprozomib


title: du145_DU145PS4B_F11_DMSO_0_24

value: DMSO

value: ATCC


title: du145_DU145PS4B_F04_LY2835219_0.5_24

value: male


title: du145_DU145PS4B_F05_Pixantrone_6_24

value: Pixantrone


title: du145_DU145PS4B_F01_EpothiloneB_0.0006_24

value: EpothiloneB


title: du145_DU145PS4B_E11_DMSO_0_24


title: du145_DU145PS4B_E09_Vadimezan_1_24

value: Vadimezan


title: du145_DU145PS4B_F02_Satraplatin_1.5_24

value: Satraplatin


title: du145_DU145PS4B_E12_SRT1720_1_24


title: du145_DU145PS4B_E06_UNTREATED__24


title: du145_DU145PS4B_G03_AP1903_1_24


title: du145_DU145PS4B_G08_Triapine_1_24

value: Triapine


title: du145_DU145PS4B_E05_EPZ-6438_2_24


title: du145_DU145PS4B_E07_Vindesine_0.02_24

value: Vindesine


title: du145_DU145PS4B_F08_Birinapant_4.5_24

value: Birinapant


title: du145_DU145PS4B_F03_Entospletinib_2_24

value: Entospletinib


title: du145_DU145PS4B_E03_Refametinib_0.155_24

value: Refametinib


title: du145_DU145PS4B_E04_UCN01_0.02_24


title: du145_DU145PS4B_E08_OTX015_0.1_24


title: du145_DU145PS4B_D12_MNS_4-Methylenedioxy-??-nitrostyrene)_4_24


title: du145_DU145PS4B_E02_NLG919_10_24


title: du145_DU145PS4B_E01_EPZ5676_6_24


title: du145_DU145PS4B_D09_Resminostat_0.155_24

value: Resminostat


title: du145_DU145PS4B_D10_Tasquinimod_0.5_24

value: Tasquinimod


title: du145_DU145PS4B_D08_Tariquidar_2_24

value: Tariquidar


title: du145_DU145PS4B_D07_Pevonedistat_0.005_24

value: Pevonedistat


title: du145_DU145PS4B_D06_DMSO_0_24


title: du145_DU145PS4B_E10_PD173074_4_24


title: du145_DU145PS4B_D05_LCL161_7_24


title: du145_DU145PS4B_D03_Propranolol_1.5_24

value: Propranolol


title: du145_DU145PS4B_D01_Perifosine_10_24

value: Perifosine


title: du145_DU145PS4B_D04_Iniparib_10_24

value: Iniparib

value: ATCC


title: du145_DU145PS4B_D02_UNTREATED__24

value: UNTREATED

value: male


title: du145_DU145PS4B_C11_ISCK03_1_24


title: du145_DU145PS4B_C05_Cabergoline_0.0001_24

value: Cabergoline


title: du145_DU145PS4B_C07_Fotemustine_7_24

value: Fotemustine


title: du145_DU145PS4B_C12_BIX01294_1.5_24


title: du145_DU145PS4B_C10_Plinabulin_0.02_24

value: Plinabulin


title: du145_DU145PS4B_C08_Binimetinib_1_24

value: Binimetinib


title: du145_DU145PS4B_C06_DMSO_0_24

value: DMSO


title: du145_DU145PS4B_C02_UNTREATED__24


title: du145_DU145PS4B_C01_ENMD2076_1.5_24


title: du145_DU145PS4B_C04_AVN944_0.09_24


title: du145_DU145PS4B_B12_AZD7762_0.5_24


title: du145_DU145PS4B_C09_Glasdegib_3_24

value: Glasdegib


title: du145_DU145PS4B_B10_ONO4059_2_24


title: du145_DU145PS4B_C03_Gilteritinib_1_24

value: Gilteritinib


title: du145_DU145PS4B_B08_Pacritinib_1.5_24

value: Pacritinib


title: du145_DU145PS4B_B07_AMG208_2.5_24


title: du145_DU145PS4B_B09_Idasanutlin_10_24

value: Idasanutlin


title: du145_DU145PS4B_B05_AVL292_0.5_24


title: du145_DU145PS4B_B03_Tasisulam_6_24

value: Tasisulam


title: du145_DU145PS4B_B02_DMSO_0_24


title: du145_DU145PS4B_B01_ATN161_10_24


title: du145_DU145PS4B_A12_SGI-1776 free base_2_24

value: SGI-1776 free base


title: du145_DU145PS4B_A11_Fedratinib_3_24

value: Fedratinib


title: du145_DU145PS4B_D11_CDDO-Me_0.5_24

value: CDDO-Me


title: du145_DU145PS4B_A10_Abexinostat_0.055_24

value: Abexinostat


title: du145_DU145PS4B_A09_PX12_1_24

value: ATCC


title: du145_DU145PS4B_A08_Ezatiostat_1.5_24

value: Ezatiostat


title: du145_DU145PS4B_A05_BIIB021_0.1_24

value: male


title: du145_DU145PS4B_A07_Gedatolisib_0.03_24

value: Gedatolisib


title: du145_DU145PS4B_B11_Cpd188_5_24


title: du145_DU145PS4B_A03_Selinexor_0.01_24

value: Selinexor


title: du145_DU145PS4B_B06_Canertinib_1_24

value: Canertinib


title: du145_DU145PS4A_H12_PP-121_1_24


title: du145_DU145PS4B_A06_ODM201_4_24


title: du145_DU145PS4B_A02_DMSO_0_24


title: du145_DU145PS4B_A01_P27600_0.28_24


title: du145_DU145PS4B_A04_Lexibulin_0.06_24

value: Lexibulin


title: du145_DU145PS4A_H08_Danusertib_0.5_24

value: Danusertib


title: du145_DU145PS4A_H11_UNTREATED__24

value: UNTREATED


title: du145_DU145PS4A_H07_Tirapazamine_10_24

value: Tirapazamine


title: du145_DU145PS4A_H05_Prinomastat_0.5_24

value: Prinomastat


title: du145_DU145PS4A_H10_Dorsomorphin 2HCl_2_24

value: Dorsomorphin 2HCl


title: du145_DU145PS4A_H04_ADH1_10_24


title: du145_DU145PS4A_H03_Raltitrexed_0.02_24

value: Raltitrexed


title: du145_DU145PS4A_H02_Talampanel_1_24

value: Talampanel


title: du145_DU145PS4A_G12_Akt Inhibitor IV_0.5_24

value: Akt Inhibitor IV


title: du145_DU145PS4A_G10_LAQ824_0.025_24


title: du145_DU145PS4A_G09_Baricitinib_0.5_24

value: Baricitinib


title: du145_DU145PS4A_G11_UNTREATED__24


title: du145_DU145PS4A_G08_Triapine_1_24

value: Triapine


title: du145_DU145PS4A_G06_Atrasentan_1.5_24

value: Atrasentan

value: ATCC


title: du145_DU145PS4A_G07_Pilaralisib_10_24

value: Pilaralisib

value: male


title: du145_DU145PS4A_G04_Pirarubicin_0.005_24

value: Pirarubicin


title: du145_DU145PS4A_G05_Halofuginone_0.0013_24

value: Halofuginone


title: du145_DU145PS4A_G02_Galeterone_3.5_24

value: Galeterone


title: du145_DU145PS4A_F12_BI-87G3_3.5_24


title: du145_DU145PS4A_H09_Tandutinib_1_24

value: Tandutinib


title: du145_DU145PS4A_G01_SCIO469_4.5_24


title: du145_DU145PS4A_F11_DMSO_0_24

value: DMSO


title: du145_DU145PS4A_F09_Oprozomib_0.02_24

value: Oprozomib


title: du145_DU145PS4A_F10_NH125_0.5_24


title: du145_DU145PS4A_H06_Picoplatin_5_24

value: Picoplatin


title: du145_DU145PS4A_F08_Birinapant_4.5_24

value: Birinapant


title: du145_DU145PS4A_F07_Voreloxin_0.11_24

value: Voreloxin


title: du145_DU145PS4A_F05_Pixantrone_6_24

value: Pixantrone


title: du145_DU145PS4A_F04_LY2835219_0.5_24


title: du145_DU145PS4A_F01_EpothiloneB_0.0006_24

value: EpothiloneB


title: du145_DU145PS4A_F02_Satraplatin_1.5_24

value: Satraplatin


title: du145_DU145PS4A_H01_LY2228820_0.045_24


title: du145_DU145PS4A_E11_DMSO_0_24


title: du145_DU145PS4A_E10_PD173074_4_24


title: du145_DU145PS4A_E09_Vadimezan_1_24

value: Vadimezan


title: du145_DU145PS4A_E07_Vindesine_0.02_24

value: Vindesine


title: du145_DU145PS4A_G03_AP1903_1_24

value: ATCC


title: du145_DU145PS4A_E06_UNTREATED__24

value: UNTREATED


title: du145_DU145PS4A_E08_OTX015_0.1_24

value: male


title: du145_DU145PS4A_E05_EPZ-6438_2_24


title: du145_DU145PS4B_B04_Talazoparib_0.06_24

value: Talazoparib


title: du145_DU145PS4A_E01_EPZ5676_6_24


title: du145_DU145PS4A_D08_Tariquidar_2_24

value: Tariquidar


title: du145_DU145PS4A_D09_Resminostat_0.155_24

value: Resminostat


title: du145_DU145PS4A_F03_Entospletinib_2_24

value: Entospletinib


title: du145_DU145PS4A_F06_UNTREATED__24


title: du145_DU145PS4A_D11_CDDO-Me_0.5_24

value: CDDO-Me


title: du145_DU145PS4A_D10_Tasquinimod_0.5_24

value: Tasquinimod


title: du145_DU145PS4A_D07_Pevonedistat_0.005_24

value: Pevonedistat


title: du145_DU145PS4A_D12_MNS_4-Methylenedioxy-??-nitrostyrene)_4_24


title: du145_DU145PS4A_E12_SRT1720_1_24


title: du145_DU145PS4A_D02_UNTREATED__24


title: du145_DU145PS4A_D01_Perifosine_10_24

value: Perifosine


title: du145_DU145PS4A_C11_ISCK03_1_24


title: du145_DU145PS4A_D03_Propranolol_1.5_24

value: Propranolol


title: du145_DU145PS4A_D04_Iniparib_10_24

value: Iniparib


title: du145_DU145PS4A_D06_DMSO_0_24

value: DMSO


title: du145_DU145PS4A_C09_Glasdegib_3_24

value: Glasdegib


title: du145_DU145PS4A_E04_UCN01_0.02_24


title: du145_DU145PS4A_C08_Binimetinib_1_24

value: Binimetinib


title: du145_DU145PS4A_C10_Plinabulin_0.02_24

value: Plinabulin


title: du145_DU145PS4A_E03_Refametinib_0.155_24

value: Refametinib

value: ATCC


title: du145_DU145PS4A_E02_NLG919_10_24

value: male


title: du145_DU145PS4A_C07_Fotemustine_7_24

value: Fotemustine


title: du145_DU145PS4A_C06_DMSO_0_24


title: du145_DU145PS4A_C04_AVN944_0.09_24


title: du145_DU145PS4A_D05_LCL161_7_24


title: du145_DU145PS4A_C05_Cabergoline_0.0001_24

value: Cabergoline


title: du145_DU145PS4A_C03_Gilteritinib_1_24

value: Gilteritinib


title: du145_DU145PS4A_B12_AZD7762_0.5_24


title: du145_DU145PS4A_B11_Cpd188_5_24


title: du145_DU145PS4A_C01_ENMD2076_1.5_24


title: du145_DU145PS4A_C12_BIX01294_1.5_24


title: du145_DU145PS4A_B09_Idasanutlin_10_24

value: Idasanutlin


title: du145_DU145PS4A_B10_ONO4059_2_24


title: du145_DU145PS4A_B07_AMG208_2.5_24


title: du145_DU145PS4A_B06_Canertinib_1_24

value: Canertinib


title: du145_DU145PS4A_B03_Tasisulam_6_24

value: Tasisulam


title: du145_DU145PS4A_B01_ATN161_10_24


title: du145_DU145PS4A_A12_SGI-1776 free base_2_24

value: SGI-1776 free base


title: du145_DU145PS4A_C02_UNTREATED__24

value: UNTREATED


title: du145_DU145PS4A_B02_DMSO_0_24


title: du145_DU145PS4A_A11_Fedratinib_3_24

value: Fedratinib


title: du145_DU145PS4A_B08_Pacritinib_1.5_24

value: Pacritinib


title: du145_DU145PS4A_A08_Ezatiostat_1.5_24

value: Ezatiostat


title: du145_DU145PS4A_B05_AVL292_0.5_24


title: du145_DU145PS4A_A09_PX12_1_24


title: du145_DU145PS4A_A07_Gedatolisib_0.03_24

value: Gedatolisib


title: du145_DU145PS4A_B04_Talazoparib_0.06_24

value: Talazoparib


title: du145_DU145PS4A_A05_BIIB021_0.1_24


title: du145_DU145PS4A_A06_ODM201_4_24


title: du145_DU145PS4A_A04_Lexibulin_0.06_24

value: Lexibulin


title: du145_DU145PS4A_A03_Selinexor_0.01_24

value: Selinexor


title: du145_DU145PS4A_A10_Abexinostat_0.055_24

value: Abexinostat

value: ATCC


title: du145_DU145PS4A_A02_DMSO_0_24

value: DMSO

value: male


title: Aneurysm 3-50: macrophage, scRNAseq

city: Suita City

first: Akihiro

last: Okada

state: Osaka

address: 6-1 Kishibe-Shinmachi

department: Department of Molecular Pharmacology

country: Japan

institute: National Cerebral and Cardiovascular Center

library_source: transcriptomic single cell

data_processing:
Paired-end sequencing (2 × 75 base pair) was performed on a NextSeq500 (Illumina). Each read was then mapped to the Rattus norvegicus reference genome (Rnor6) using CLC genomics workbench (version 11, QIAGEN). Differential expression analyses, including principal component analysis and clustering analysis, were performed using the iDEP.951.
Assembly: Rnor6
Supplementary files format and content: Macrophages in aneurysm lesions.xlsx represents counts for all genes for all samples.

organism: Rattus norvegicus

source_name: Artery

extract_protocol:
DiI-containing nanoparticles were intravenously injected in rats to label macrophages infiltrating in lesions. After 3 days, DiI-labelled macrophages were then isolated from the lesions in a single-cell fashion by the laser-microdissection technique.
The library for single cell RNA-sequencing analysis was prepared by a SMART-Seq Single Cell Plus Kit.

treatment_protocol: Under general anesthesia by the inhalation of isoflurane (induction; 5.0 %, maintenance; 1.5~2.0 %), the left common carotid artery (CCA) was cut in the proximal portion and was anastomosed to the right CCA in an end-to-side fashion with a 10-0 nylon suture to create a bifurcation. Hyper-volemic state was also induced by salt overloading and ligation of the left renal artery. Immediately after the above surgical manipulations, animals were fed the chow containing 8 % sodium chloride and 0.12 % 3-aminopropionitrile, an inhibitor of lysyl oxidase that catalyzes the cross-linking of collagen and elastin.

tag: disease state

value: aneurysm model

tag: animal id

value: Macrophages

tag: tissue

value: Artery

tag: strain

value: Sprague Dawley

value: 7 weeks old


title: Aneurysm 3-49: macrophage, scRNAseq


title: du145_DU145PS3B_H11_UNTREATED__24

value: UNTREATED


title: Aneurysm 3-48: macrophage, scRNAseq


title: du145_DU145PS4A_A01_P27600_0.28_24


title: Aneurysm 3-51: macrophage, scRNAseq


title: du145_DU145PS3B_H10_CC223_1_24


title: Aneurysm 3-47: macrophage, scRNAseq


title: Aneurysm 3-45: macrophage, scRNAseq


title: Aneurysm 3-44: macrophage, scRNAseq


title: Aneurysm 3-43: macrophage, scRNAseq


title: du145_DU145PS3B_H08_Triciribine_0.135_24

value: Triciribine


title: du145_DU145PS3B_H12_Vatalanib_0.115_24

value: Vatalanib


title: Aneurysm 3-46: macrophage, scRNAseq


title: du145_DU145PS3B_H09_Mocetinostat_0.165_24

value: Mocetinostat


title: du145_DU145PS3B_H06_Nintedanib_0.135_24

value: Nintedanib


title: Aneurysm 3-42: macrophage, scRNAseq


title: du145_DU145PS3B_H07_LY2603618_0.5_24


title: du145_DU145PS3B_H05_CP724714_1.5_24


title: Aneurysm 3-52: macrophage, scRNAseq


title: du145_DU145PS3B_H03_ABT751_1_24


title: Aneurysm 3-41: macrophage, scRNAseq


title: Aneurysm 3-39: macrophage, scRNAseq


title: Aneurysm 3-40: macrophage, scRNAseq


title: DNA methylation in 293FT ARID1A WT Clone20 at 4w

type: genomic

city: Tokyo

first: Harumi

last: Yamada

address: 2-4-41 Ebara Shinagawa-ku

department: Department of Epigenomics

institute: Hoshi University

description: Normal cells

hyb_protocol: Standard Illumina Protocol

scan_protocol: The array was scanned with an iScan System.

data_processing:
The data were analyzed using GenomeStudio Methylation Module Software.
The non_normalized.txt contains unmethylated and methylated signal intensities

label: Cy5 and Cy3

molecule: genomic DNA

source_name: DNA methylation in 293FT ARID1A WT

label_protocol: Standard Illumina Protocol

growth_protocol: Cells were maintained in DMEM medium.

extract_protocol: Genomic DNA was extracted by standard phenol/chloroform method, and was quantified using a Quant-iT PicoGreen dsDNA Assay Kit (Life Technologies).

tag: cell line background

tag: genotype/variation

value: ARID1A WT

tag: cloneid/time point

value: clone20 at 4w


title: du145_DU145PS3B_H04_Givinostat_0.025_24

value: Givinostat


title: Aneurysm 3-38: macrophage, scRNAseq


title: Aneurysm 3-37: macrophage, scRNAseq


title: du145_DU145PS3B_G12_Cyproterone_0.165_24

value: Cyproterone


title: DNA methylation in 293FT ARID1A KO Clone50 at 20w

description: Normal cells

source_name: DNA methylation in 293FT ARID1A KO

value: ARID1A KO

value: clone50 at 20w


title: Aneurysm 3-36: macrophage, scRNAseq

value: male


title: du145_DU145PS3B_G11_UNTREATED__24

value: ATCC


title: DNA methylation in 293FT ARID1A KO Clone50 at 4w

description: Normal cells

value: clone50 at 4w


title: Aneurysm 3-35: macrophage, scRNAseq

value: aneurysm model

value: Macrophages

value: Artery


title: Aneurysm 3-34: macrophage, scRNAseq

value: Sprague Dawley

value: 7 weeks old


title: du145_DU145PS3B_G10_INK128_0.015_24


title: Aneurysm 3-33: macrophage, scRNAseq


title: Aneurysm 3-32: macrophage, scRNAseq


title: DNA methylation in 293FT ARID1A KO Clone78 at 20w

description: Normal cells

value: clone78 at 20w


title: du145_DU145PS3B_H02_Savolitinib_10_24

value: Savolitinib


title: DNA methylation in 293FT ARID1A KO Clone6 at 4w

description: Normal cells

value: clone6 at 4w


title: DNA methylation in 293FT ARID1A KO Clone78 at 4w

description: Normal cells

value: clone78 at 4w


title: DNA methylation in 293FT

description: Normal cells

source_name: DNA methylation in 293FT

value: control


title: DNA methylation in 293FT ARID1A WT Clone23 at 0w

description: Normal cells

value: ARID1A WT

value: clone23 at 0w


title: du145_DU145PS3B_G08_AZ12823138_10_24


title: Aneurysm 3-31: macrophage, scRNAseq


title: Aneurysm 3-30: macrophage, scRNAseq


title: DNA methylation in 293FT ARID1A WT Clone20 at 0w

description: Normal cells

value: clone20 at 0w


title: Aneurysm 3-29: macrophage, scRNAseq


title: DNA methylation in 293FT ARID1A KO Clone50 at 0w

description: Normal cells

value: ARID1A KO

value: clone50 at 0w


title: DNA methylation in 293FT ARID1A WT Clone23 at 4w

description: Normal cells

value: clone23 at 4w


title: Aneurysm 2-27: macrophage, scRNAseq

value: male


title: du145_DU145PS3B_G07_Rocilinostat_0.16_24

value: Rocilinostat

value: ATCC


title: du145_DU145PS3B_G06_RAF265_0.04_24


title: Aneurysm 2-26: macrophage, scRNAseq

value: aneurysm model

value: Macrophages

value: Artery


title: DNA methylation in 293FT ARID1A KO Clone6 at 0w

description: Normal cells

value: clone6 at 0w


title: DNA methylation in 293FT ARID1A KO Clone78 at 0w

description: Normal cells

value: clone78 at 0w


title: du145_DU145PS3B_G05_Eniluracil_4_24

value: Eniluracil


title: Aneurysm 2-23: macrophage, scRNAseq

value: Sprague Dawley

value: 7 weeks old


title: DNA methylation in 293FT ARID1A WT Clone4 at 0w

description: Normal cells

value: ARID1A WT

value: clone4 at 0w


title: Aneurysm 2-28: macrophage, scRNAseq


title: DNA methylation in 293FT ARID1A WT Clone4 at 20w

description: Normal cells

value: clone4 at 20w


title: Aneurysm 2-22: macrophage, scRNAseq


title: du145_DU145PS3B_G04_Brigatinib_0.035_24

value: Brigatinib


title: N1

city: Hangzhou

first: Zhen-Chao

last: Zhou

address: Yuhangtang Road

country: China

institute: Zhejiang University

data_processing:
Illumina Casava1.7 software used for basecalling.
Sequenced reads were trimmed for adaptor sequence, and masked for low-complexity or low-quality sequence, then mapped to mm8 whole genome using Hisat2
Reads Per Kilobase of exon per Megabase of library size (RPKM) were calculated using a protocol from Chepelev et al., Nucleic Acids Research, 2009. In short, exons from all isoforms of a gene were merged to create one meta-transcript. The number of reads falling in the exons of this meta-transcript were counted and normalized by the size of the meta-transcript and by the size of the library.
Genome_build: mm9
Supplementary_files_format_and_content: raw counts

organism: Escherichia coli HB101

source_name: bacteria

extract_protocol:
QIAGEN miRNeasy Mini Kit (QIAGEN, Germany)
RNA libraries were prepared for sequencing using standard Illumina protocols

tag: agent


title: DNA methylation in 293FT ARID1A KO Clone6 at 20w

description: Normal cells

value: ARID1A KO

value: clone6 at 20w


title: Aneurysm 2-21: macrophage, scRNAseq

value: male


title: Aneurysm 2-20: macrophage, scRNAseq


title: du145_DU145PS3B_G03_Ispinesib_0.001_24

value: Ispinesib


title: HeLa_M11C_KO

city: Canberra

first: Pablo

last: Acera Mateos

state: ACT

address: 131 Garran Rd

department: The Shine-Dalgarno Centre for RNA Innovation

country: Australia

institute: ANU

description: Direct-RNA sequencing

data_processing:
The processed files were generating using the CHEUI pipeline (https://github.com/comprna/CHEUI-public)
Supplementary files format and content: data format is .xlsx containing significant RNA modifications called using CHEUI. Columns indicate Column 1: Chromosome; column 2: genomic start position (half-open) of the modified site; column 3: genomic end position of the modified site; column 4: transcript unique ID; column 5: score (not used); column 6: genomic strand; column 7: Transcript position (half-open) of the modified nucleotide; column 8: site motif; column 9: site coverage (number of reads); column 10: site stoichiometry; column 11: modified site probability; column 12: Transcript type; column 13: Gene name; column 14: Gene unique ID; column 15: transcript length (nts); column 16: transcript CDS length (nts); column 17: transcript 5’UTR length (nts); column 18: 3’UTR length (nts); column 19: CDS start in transcript coordinates; column 20: CDS end in transcript coordinates; column 21: site position relative to the transcript segments (see Methods). Ranges from 0 to 3. From 0-1 corresponds to start and end of 5’UTR; 1-2 corresponds to start and end of CDS, 2-3 corresponds to start and end of 3’UTR; column 22: abs_cds_start, absolute distance in nucleotides of the site from the annotated start of the CDS; column 23: abs_cds_end absolute distance in nucleotides of the site from the annotated end of the CDS; column 23: distance from the site to the closest junction upstream; column 24: distance from the site to the closest junction downstream; column 25: Sample name column 26: model (m6A or m5C).

molecule: polyA RNA

source_name: HeLa

growth_protocol: HeLa cells (human cervical cancer) were obtained from ATTC and confirmed via short tandem repeat (STR) profiling with CellBank Australia. Cells were grown in DMEM medium (Gibco) supplemented with 10% FBS and 1× antibiotic-antimycotic solution (Sigma) and passaged when 70–90% confluent.

extract_protocol:
3 WT and 3 NSUN2-KO 80% confluent 10 cm plates were washed twice in ice-cold PBS and scraped in 500 µl of denaturing lysis and binding buffer (100 mM Tris-HCl pH 7.4, 1 % w/v lithium dodecyl sulfate (LiDS), 0.8 M lithium chloride, 40 mM EDTA and 8 mM DTT; LBB). The cell lysate was thoroughly pipetted with 200 µl tip until the sample viscosity was reduced, and pipetting was seamless. 500 µl of oligo(dT)25 magnetic beads (New England BioLabs) suspension was used per replicate. The beads were washed with 1 ml of LBB twice, each time collecting the beads on a magnet and completely removing the supernatant. Upon washing, the oligo(dT)25 beads were resuspended in the cell lysate and placed in a rotator set for 20 rpm at 25 °C for 5 minutes, followed by the same rotation at 4 °C for 30 minutes. The suspension was briefly spun down at 12,000 g, separated on a magnet, and the supernatant was discarded. The beads were then resuspended with 1 ml of wash buffer (20 mM Tris-HCl pH 7.4, 0.2 % v/v Titron X-100, 0.4 M lithium chloride, 10 mM EDTA and 8 mM DTT; WB) and washed on a rotator set for 20 rpm at 4 °C for 5 minutes, using 3 rounds of washing. The beads were collected on a magnetic rack and the supernatant was discarded. The wash procedure was repeated three times. The elution was carried out stepwise. Washed bead pellet was first resuspended in 50 µl of the elution buffer (25 mM HEPES-KOH, 0.1 mM EDTA; HE). The first suspension was heated at 60 °C for 5 minutes to facilitate the elution, and the eluate was collected upon placing the bead-sample mixture on a magnetic rack, separating the beads, and recovering the clean supernatant. The resultant pellet was next resuspended in another 50 µl of HE buffer, and the process was repeated. The eluates were then combined and subjected to an additional solid phase reversible mobilization (SPRI) bead purification step and stored frozen. The eluate from oligo(dT) bead extraction was further purified using AMPure XP SPRI beads (Beckman Coulter Life Sciences) according to the manufacturer’s recommendations. Briefly, the eluate samples were supplemented with 1.2x volumes of the SPRI bead suspension in its standard (supplied) binding buffer, and the resultant mixture incubated at room temperature for 5 minutes with periodic mixing. The SPRI beads were brought down by a brief 2,000 g spin and separated from the solution on a magnetic rack. The supernatant was removed, and the beads were resuspended in 1 ml of 80 % v/v ethanol, 20 % v/v deionized water mixture and further washed by tube flipping. The bead and solution separation procedure were repeated. The ethanol washing process was repeated one more time. Any remaining liquid was brought down by a brief spin and removed using a pipette, and the beads were allowed to air-dry while in the magnetic rack for 2 minutes. The purified RNA was then eluted in deionized water and the RNA content was assessed using absorbance readout via Nanodrop and fluorescence-based detection via Qubit RNA high sensitivity (HS) assay kit (Thermo Fisher Scientific).
The library preparation followed the manufacturer’s recommendations. 650-800 ng from HeLa cells, were used for each 2× library preparation within every replicate (all recommended volumes doubled-up) with direct RNA sequencing kit (SQK-RNA002) as supplied by Oxford Nanopore Technology. The modifications were that Superscript IV RNA Polymerase (Thermo Fisher Scientific) was used, RNA Control Standard (RCS) was omitted, and RNasin Plus (Promega) was included at 1 U/ µl in all reaction solutions until the SPRI purification step after the reverse transcription reaction. The final adaptor-ligated sample was eluted in 40 µl.

treatment_protocol: Two CRISPR (cr)RNAs were designed, targeting the 5?- (exon 2 crRNA “AGGCUACCCCGAGAUCGUCA”) and 3?-proximal (exon 19 crRNA “AAUGAGAGUGCAGCCAGCAC”) regions of the gene. Gene sequences from Ensembl (Asia server) were processed via CCTop 51 to check for efficacy and predict potential off-target cleavage effects. The two sequences with highest predicted efficacy and minimal off-target effects were selected as crRNA and ordered as Alt-R CRISPR-Cas9 crRNA from Integrated DNA Technologies (IDT).

value: HeLa

tag: genotype


title: du145_DU145PS3B_G02_Banoxantrone_5_24

value: Banoxantrone

value: ATCC


title: Aneurysm 2-19: macrophage, scRNAseq

value: aneurysm model

value: Macrophages

value: Artery


title: DNA methylation in 293FT ARID1A WT Clone20 at 20w

description: Normal cells

value: clone20 at 20w


title: DNA methylation in 293FT ARID1A WT Clone23 at 20w

description: Normal cells

value: clone23 at 20w


title: Aneurysm 2-17: macrophage, scRNAseq

value: Sprague Dawley

value: 7 weeks old


title: HeLa_M11C_WT

description: Direct-RNA sequencing

value: WT


title: Aneurysm 2-16: macrophage, scRNAseq


title: Aneurysm 2-18: macrophage, scRNAseq


title: du145_DU145PS3B_G09_AZ12609721_1_24


title: Aneurysm 2-15: macrophage, scRNAseq


title: du145_DU145PS3B_H01_Phenelzine_1_24

value: Phenelzine


title: du145_DU145PS3B_G01_Berberine_7_24

value: Berberine


title: HeLa_M11B_KO

description: Direct-RNA sequencing


title: du145_DU145PS3B_F12_Cilengitide_10_24

value: Cilengitide


title: du145_DU145PS3B_F11_DMSO__24

value: DMSO


title: Aneurysm 2-11: macrophage, scRNAseq

value: male


title: Aneurysm 2-13: macrophage, scRNAseq


title: HeLa_M11B_WT

description: Direct-RNA sequencing


title: DNA methylation in 293FT ARID1A WT Clone4 at 4w

description: Normal cells

value: ARID1A WT

value: clone4 at 4w


title: HeLa_M11A_KO

description: Direct-RNA sequencing

value: HeLa


title: du145_DU145PS3B_F10_MLN2480_6.5_24

value: ATCC


title: HeLa_M11A_WT

description: Direct-RNA sequencing


title: du145_DU145PS3B_F09_Tacedinaline_1_24

value: Tacedinaline


title: Aneurysm 2-8: macrophage, scRNAseq

value: aneurysm model

value: Macrophages


title: Aneurysm 2-7: macrophage, scRNAseq

value: Artery


title: Aneurysm 2-6: macrophage, scRNAseq


title: utricle, OVX+raloxifene  (DK21227_20)

city: Toon

first: Takahiro

last: Nakata

address: Shitsukawa

department: Otolaryngology, Head and Neck Surgery

institute: Ehime University Graduate School

data_processing:
CLC Genomics Workbench
Sequence data were trimmed for adaptor and polyA sequences and low-quality nucleotides using CLC Genomics Workbench.
The trimmed fastq was mapped to the mus musculus (GRCm39.105) using CLC Genomics Workbench.
Sequence data analysis and normalization were performed using CLC Genomics Workbench.
Assembly: GRCm39.105
Supplementary files format and content: Difference expression analysis was performed by the CPM (TMM) normalization method.

organism: Mus musculus

source_name: utricle

growth_protocol: C57BL/6J female mice were ovariectomized or sham-operated at eight weeks of age.

extract_protocol:
RNA was extracted using the NucleoSpin RNA XS kit (Macherey-Nagel). 1 ng of total RNA was used for the construction of sequencing libraries.
RNA libraries for RNA-seq were prepared using QantSeq 3' mRNA-Seq Library Prep Kit (LEXOGEN).

treatment_protocol: In the OVX mice, the pellets were implanted subcutaneously: estradiol (50µg/60days) or raloxifene (2.4mg/60days) or vehicle. In the sham mice, the vehicle pellet was implanted subcutaneously.

value: utricle

value: OVX+raloxifene


title: utricle, OVX+raloxifene  (DK21227_19)


title: Aneurysm 1-5: macrophage, scRNAseq

value: Sprague Dawley

value: 7 weeks old


title: Aneurysm 1-4: macrophage, scRNAseq


title: du145_DU145PS3B_F07_Ganetespib_0.005_24

value: Ganetespib


title: utricle, OVX+raloxifene  (DK21227_18)


title: Aneurysm 1-3: macrophage, scRNAseq


title: Aneurysm 1-2: macrophage, scRNAseq


title: Aneurysm 2-12: macrophage, scRNAseq


title: Aneurysm 2-14: macrophage, scRNAseq


title: du145_DU145PS3B_F05_AT9283_1_24


title: utricle, OVX+raloxifene  (DK21227_17)


title: Aneurysm 2-24: macrophage, scRNAseq


title: utricle, OVX+raloxifene  (DK21227_16)


title: du145_DU145PS3B_F04_Dacomitinib_0.001_24

value: Dacomitinib


title: UAC1 [miRNA-Seq]

city: Jiamusi

first: Fan

last: Wu

address: Southwest Gang Street

institute: Jiamusi University

description: Small RNA

data_processing:
Subsequently, unique sequences with length in 18~25 nucleotide were mapped to specific species precursors in miRBase 22.0 by BLAST search to identify known miRNAs and novel 3p- and 5p- derived miRNAs.
Length variation at both 3' and 5' ends and one mismatch inside of the sequence were allowed in the alignment.
The unique sequences mapping to specific species mature miRNAs in hairpin arms were identified as known miRNAs. The unique sequences mapping to the other arm of known specific species precursor hairpin opposite to the annotated mature miRNA-containing arm were considered to be novel 5p- or 3p-derived miRNA candidates.
The remaining sequences were mapped to other selected species precursors (with the exclusion of specific species) in miRBase 22.0 by BLAST search, and the mapped pre-miRNAs were further BLASTed against the specific species genomes to determine their genomic locations.
The above two we defined as known miRNAs. The unmapped sequences were BLASTed against the genomes, and the hairpin RNA structures containing sequences were predicated from the flank 120 nt sequences using RNAfold software (http://rna.tbi.univie.ac. at/cgi-bin/RNAfold.cgi). The criteria for secondary structure prediction were: (1) number of nucleotides in one bulge in stem (≤12) (2) number of base pairs in the stem region of the predicted hairpin (≥16) (3) cutoff of free energy (kCal/mol ≤-15) (4) length of hairpin (up and down stems + terminal loop ≥50) (5) length of hairpin loop (≤200). (6) number of nucleotides in one bulge in mature region (≤4) (7) number of biased errors in one bulge in mature region (≤2) (8) number of biased bulges in mature region (≤2) (9) number of errors in mature region (≤4) (10) number of base pairs in the mature region of the predicted hairpin (≥12) (11) percent of mature in stem (≥80).
Supplementary files format and content: excel,expression profiles

source_name: condylar cartilage

extract_protocol:
Total RNA was extracted using Trizol reagent (Invitrogen, CA, USA) following the manufacturer's procedure
Approximately 5 µg of total RNA were used to prepare nine small RNA librariesaccording to the protocol of TruSeq Small RNA Sample Prep Kits (Illumina, San Diego, CA, USA). And then the libraries were sequenced by Illumina Hiseq 2500 at the LC-BIO following the vendor’s recommended protocol. Raw reads were subjected to an in-house program, ACGT101-miR (LC Sciences, Houston, Texas, USA) to remove adapter dimers, junk, low complexity, common RNA families (rRNA, tRNA, snRNA, snoRNA) and repeats.

value: Sprague-Dawley

value: condylar cartilage

value: unilateral anterior crossbite, 8 weeks


title: du145_DU145PS3B_F06_UNTREATED__24

value: UNTREATED

value: male


title: du145_DU145PS3B_F08_Quizartinib_1.5_24

value: Quizartinib


title: CON1 [miRNA-Seq]

description: Small RNA

value: control, 8weeks


title: utricle, OVX+estradiol (DK21227_14)

value: OVX+estradiol


title: CON3 [miRNA-Seq]

description: Small RNA


title: utricle, OVX+estradiol (DK21227_15)


title: UAC3 [miRNA-Seq]

description: Small RNA


title: Aneurysm 2-10: macrophage, scRNAseq

value: aneurysm model


title: du145_DU145PS3B_F03_Acalabrutinib_1.5_24

value: Acalabrutinib

value: ATCC


title: du145_DU145PS3B_F02_ARN509_10_24


title: Aneurysm 1-1: macrophage, scRNAseq

value: Macrophages

value: Artery


title: utricle, OVX+estradiol (DK21227_13)

value: utricle


title: utricle, OVX+estradiol (DK21227_12)


title: du145_DU145PS3B_F01_Aminopterin_1_24

value: Aminopterin


title: du145_DU145PS3B_E12_Sotrastaurin_3_24

value: Sotrastaurin


title: utricle, OVX+estradiol (DK21227_11)


title: UAC2 [miRNA-Seq]

description: Small RNA


title: du145_DU145PS3B_E11_DMSO__24

value: DMSO


title: CON2 [miRNA-Seq]

description: Small RNA

value: Sprague-Dawley


title: du145_DU145PS3B_E10_RO4929097_0.5_24


title: utricle, OVX+vehicle (DK21227_10)

description:
Expression_Browser_sham_vs_ovx.txt
Expression_Browser_E2_vs_ovx.txt
Expression_Browser_RAL_vs_ovx.txt

value: OVX+vehicle


title: utricle, OVX+vehicle (DK21227_09)


title: du145_DU145PS3B_E09_CPI613_0.005_24


title: utricle, OVX+vehicle (DK21227_08)


title: du145_DU145PS3B_E08_Galunisertib_2.5_24

value: Galunisertib


title: utricle, OVX+vehicle (DK21227_07)


title: du145_DU145PS3B_E07_Crenolanib_0.145_24

value: Crenolanib


title: utricle, OVX+vehicle (DK21227_06)


title: Aneurysm 2-25: macrophage, scRNAseq

value: Sprague Dawley

value: 7 weeks old

value: male


title: utricle, sham operation+vehicle (DK21227_05)

value: sham operation+vehicle


title: SAMPLE 47_hMSC_passage 16

type: RNA

city: Tsukuba

first: Yuzuru

last: Ito

state: Ibaraki

address: Central 6, Higashi 1-1-1

department: Biotechnology Research Institute for Drug Discovery

institute: National Institute of Advanced Industrial Science and Technology (AIST)

description: Gene expression in human mesenchymal stem cells

hyb_protocol: 0.6 ug of Cy3-labelled cRNA (specific activity >6.0 pmol Cy3/ug cRNA) was fragmented at 60°C for 30 minutes in a reaction volume of 25 ul containing 1x Agilent fragmentation buffer and 2x Agilent blocking agent following the manufacturers instructions. On completion of the fragmentation reaction, 55 ul of 2x HiRPM Hybridization Buffer was added to the fragmentation mixture and 480 ng cRNA was hybridized to Agilent SurePrint G3 Human GE 8x60K Microarray Kit (G4851A) for 17 hours at 65°C in a rotating Agilent hybridization oven. After hybridization, microarrays were washed 1 minute at room temperature with GE Wash Buffer 1 (Agilent) and 1 minute with 37°C GE Wash buffer 2 (Agilent), then dried immediately by brief centrifugation.

scan_protocol: Slides were scanned immediately after washing on the Agilent DNA Microarray Scanner (G2505C) using one color scan setting for 8x60k array slides.

data_processing:
The scanned images were analyzed with Feature Extraction Software GX14.9.1 (Agilent) using default parameters.
Signal intensities of <1 were set to 1, and each chip was normalized to the 75th percentiles of all measurements from that chips. Baseline transformation of these data was not performed.

source_name: hMSC, passage 16

label_protocol: Cyanine-3 (Cy3) labeled cRNA was prepared from 150 ng of total RNA using Low Input Quick Amp Labeling Kit (Agilent) according to the manufacturer's instructions, followed by RNeasy column purification (QIAGEN). Dye incorporation and cRNA yield were checked with the NanoDrop ND-1000 Spectrophotometer.

growth_protocol: Human mesenchymal stem cells, hMSC, was cultured in MesenPRO RS medium (Gibco, 12746012) supplemented with 2 mM L-glutamine (Gibco, 25030-81) and 1 % Penicillin-Streptomycin (Gibco, 15140-122) at 37 ℃ in a humidified atmosphere of 5 % CO2.

extract_protocol: Total RNA was prepared by using ISOGEN (Nippon Gene) following the manufacturer's recommendations. RNA was quantified using a NanoDrop-1000 spectrophotometer.

value: hMSC

tag: tissue source

value: Human bone marrow

value: Human mesenchymal stem cells (hMSC)

tag: passage

value: passage 16


title: SAMPLE 40_hMSC_passage 12

source_name: hMSC, passage 12

tag: cell line

value: passage 12


title: SAMPLE 48_hMSC_passage 16


title: SAMPLE 45_hMSC_passage 15

source_name: hMSC, passage 15

value: passage 15


title: du145_DU145PS3B_E05_Varlitinib_0.005_24

tag: treatment

value: Varlitinib

tag: provider

value: ATCC


title: SAMPLE 35_hMSC_passage 10

source_name: hMSC, passage 10

value: passage 10


title: SAMPLE 41_hMSC_passage 13

source_name: hMSC, passage 13

value: passage 13


title: utricle, sham operation+vehicle (DK21227_04)

value: utricle


title: SAMPLE 33_hMSC_passage 9

source_name: hMSC, passage 9

value: passage 9


title: du145_DU145PS3B_E04_Combretastatin_0.2_24

value: Combretastatin

tag: vendor id

tag: age


title: SAMPLE 39_hMSC_passage 12

tag: cell type


title: SAMPLE 42_hMSC_passage 13


title: SAMPLE 37_hMSC_passage 11

source_name: hMSC, passage 11

value: passage 11


title: SAMPLE 38_hMSC_passage 11


title: SAMPLE 44_hMSC_passage 14

source_name: hMSC, passage 14

value: passage 14


title: SAMPLE 32_hMSC_passage 8

source_name: hMSC, passage 8

value: passage 8


title: SAMPLE 46_hMSC_passage 15


title: du145_DU145PS3B_E06_UNTREATED__24

source_name: prostate cancer

value: UNTREATED

tag: Sex

value: male


title: utricle, sham operation+vehicle (DK21227_03)

value: sham operation+vehicle


title: SAMPLE 31_hMSC_passage 8

value: hMSC

value: Human bone marrow

value: Human mesenchymal stem cells (hMSC)


title: SAMPLE 29_hMSC_passage 7

source_name: hMSC, passage 7

value: passage 7


title: SAMPLE 30_hMSC_passage 7


title: SAMPLE 36_hMSC_passage 10


title: SAMPLE 34_hMSC_passage 9


title: du145_DU145PS3B_E03_TAK733_0.08_24


title: utricle, sham operation+vehicle (DK21227_02)


title: du145_DU145PS3B_E02_Valproic acid_2_24

value: Valproic acid


title: utricle, sham operation+vehicle (DK21227_01)


title: du145_DU145PS3B_E01_Tacrolimus_10_24

value: Tacrolimus

value: ATCC


title: du145_DU145PS3B_D12_SAR245409_0.5_24


title: du145_DU145PS3B_D11_MK0752_10_24


title: SAMPLE 27_hMSC_passage 6

source_name: hMSC, passage 6

value: passage 6


title: SAMPLE 28_hMSC_passage 6